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DESIGN AND SYNTHESIS  OF COMPLEX BIOMACROMOLECULES AND 
THEIR USES IN VARIOUS APPLICATIONS 
SUMMARY 
The first applications of a biodegradable polymers were at 1980s. They have gained 
much attention since then by the discovery of their feasibility to biomedical 
applications such as sutures, bone screws, tissue engineering scaffolds and drug 
delivery systems. Physical properties, hydrolytic degradation profiles, and 
biocompatibility of aliphatic polyesters and co-polyesters make them incomparable 
materials within the biomedical products. Also, biodegradable polymers are of 
special interest because they do not accumulate in nor harm the environment and thus 
can be considered “green”. Polymers derived from glycolide (GA), lactide (LA), β-
butyrolactone (β-BL), ε-caprolactone (ε-CL), and trimethylcarbonate (TMC) are 
known to be the most popular ones. The main reason of popularity is degradation 
products of these polymers are toxicologically safe which are eliminated by normal 
metabolic pathways. The potential use of these biopolymers is polymeric particles as 
carriers of of a wide range of drugs and therapeutic agents. Polymeric particles such 
as micro- or nano- spheres which have the ability of delivering drugs in specified 
area and sustained periods of time are being employed to avoid the inconvenient 
surgical insertion of large implants. The drug release properties of the biodegradable 
polymeric particles can be controlled by polymer degradation under physiological 
conditions and is found to depend on copolymer ratio and molecular weight. Drug 
release from polyesters, such as poly(L-lactic acid) (PLLA) and poly(lactic-co-
glycolic acid) (PLGA), is generally controlled by both drug diffusion and polymer 
erosion. In the diffusion process, water diffuses into the polymer matrix faster than 
the polymer is degraded. The hydrolysable bonds in the whole polymer matrix are 
cleaved homogeneously. Therefore, the average molecular weight of the polymer 
decreases homogeneously. Release of the drug occurs by diffusion which is related to 
concentration of the drug. In the case of surface erosion, the diffusion rate of water 
into the polymer matrix is slower than the degradation rate of the macromolecules. 
The degradation only takes place in the thin surface layer while the molecular weight 
of the polymer in the bulk remains unchanged. 
Despite superior properties of aliphatic polyesters, they still need to be improved for 
certain applications. The basic approach behind the utilization of aliphatic polyesters 
in biomedical field is the controllable degradation behavior of the polymers. 
Hydrophilicity, surface chemistry, morphology and crosslink density are major 
factors that influences degradation rate. The degradation rate can be controlled by the 
incorporation of new segments to biodegradable aliphatic polyesters. Grafting of 
biodegradable polymer chains, such as PLGA, onto their backbone may provide new 
biomaterials with interesting properties. 
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In the current thesis, we described the synthesis of new biodegradable polymers for 
various applications in biomedical field. In this respect, we focused on introducing 
new segments to biodegradable polymers to overcome the common problems 
associated with the chemical composition of the biodegradable polymers such as the 
control of drug release, degradation behavior, and effective treatment. Controlled 
release profiles and hydrolytic degradation behaviors of suitable polymers for 
microsphere preparation are also investigated.   
There are four outcomes of thesis: 
i. Preparation of a model drug loaded microspheres from various poly(lactic-co-
glycolic acid) (PLGA) copolymers and in vitro release studies  
ii. Synthesis of polystyrene-g-poly (lactic acid) (PS-g-PLLA) and polystyrene-g-
poly (lactic-co-glycolic acid) (PS-g-PLLGA), degradation behavior of these 
polymers and in vitro release of the model drug from microspheres made of 
PS-g-PLLA, PS-g-PLLGA. 
iii. Synthesis of poly(styrene-lactic acid-ethylene glycol) (PS-PLA-PEG) 
miktoarm  star copolymer and pyrolysis studies. 
We firstly aimed to prepare microspheres made of commercial biodegradable 
polymers at different conditions. Polymers with a different molecular weights and 
compositions are used for comparison. Surface characteristics and controlled release 
profiles of synthesized microspheres are examined. Commercial PLGA copolymers 
are used for fabrication of microspheres to compare after synthesis of new 
biopolymers. Imatinib mesylate, used as model drug for the treatment of 
craniopharyngiomas which is a kind of brain tumor and grows by vascularization. 
Microspheres were prepared by double emulsion/ solvent evaporation method. 
Nearly, eighty different microspheres were synthesized and optimized microspheres 
were chosen for investigation. Influence of process parameters on microsphere 
encapsulation, initial burst release and release profile from PLGA microspheres were 
studied. In vitro release studies were performed at 37˚C in phosphate buffer saline 
solution (PBS) at pH 7.4 and release profiles of microspheres were monitored by 
high pressure chromatography (HPLC). Surface morphologies of the microspheres 
before and during release studies were determined by scanning electron microscopy 
(SEM). As a result of this work optimized microspheres were chosen for in vivo 
experiments. It is found that, local delivery of model drug using biodegradable 
microspheres may be a promising way of treatment. 
In the second part, new copolymers of commercial biopolymers are synthesized 
named PS-g-PLLA and PS-g-PLLGA to overcome the shortcomings of 
biodegradable polymers.  Hydrolytic degradation behaviors, in vitro release studies 
of a model drug from microspheres made of PS-g-PLLA and PS-g-PLLGA graft 
copolymers and surface characterization of microspheres are investigated. The graft 
copolymers were synthesized through combination of nitroxide mediated free radical 
polymerization (NMRP) and ring opening polymerization (ROP) with copper (I)-
catalyzed “Click” chemistry.  First, the click component, azido-functional PS (PS-
N3) was prepared by copolymerization of styrene and chloromethyl styrene by 
NMRP followed by the conversion of chlorine groups of the resulting copolymer to 
azido groups by using NaN3 in N, N-dimethylformamide. Propargyl functional APEs 
were prepared independently by ROP of lactic acid and glycolic acid using tin 
octoate in the presence of propargyl alcohol at 130 ˚C. Finally, PS-N3 was coupled 
with the resulting polymers by click chemistry to yield graft copolymers (PS-g-
PLLA and PS-g-PLLGA, respectively). The intermediates and final graft copolymers 
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were characterized by 1H-NMR and FT-IR spectrally, and GPC chromatographic 
analyses. The hydrolytic degradation behavior of the obtained graft copolymers in 
PBS were investigated by the weight loss and molecular weight measurements. It is 
shown that both copolymers undergo slow hydrolytic degradation, PS-g-PLLGA 
being relatively faster due to the presence of hydrophilic glycolic acid groups in the 
structure. Microspheres of the graft copolymers were prepared and characterized. In 
vitro release studies showed that PS backbone of the graft copolymers slows down 
the degradation rate and gives opportunity to control the drug release. 
In the final part, we describe the synthesis of of PS-PLA-PEG miktoarm star 
copolymer and thermal degradation behavior studies. An ABC type miktoarm star 
copolymer possessing polystyrene (PS), poly(lactic acid) (PLA) and poly(ethylene 
glycol) (PEG) arms was synthesized by combining Atom Transfer Radical 
Polymerization (ATRP) and Ring Opening Polymerization (ROP) with two click 
chemistries, namely thiol–ene and copper catalyzed azide–alkyne cycloaddition 
(CuAAC).  For this purpose, a core 1-(allyloxy)-3-azidopropan-2-ol with allyl and 
azide functionalities was synthesized in two steps. Then, clickcable polymers, 
polystyrene with thiol functionality (PS-SH) and poly(ethylene glycol) with alkyne 
functionality (PEG-acetylene) were independently prepared. As the first step of the 
grafting onto process, PS-SH was thiol–ene clicked onto the core to yield PS-N3-OH. 
The second arm was then incorporated on to the core by the Ring Opening 
Polymerization (ROP) of   l-(-)-Lactide (LA) using as PS-N3-OH initiator and tin(II) 
2-ethylhexanoate as catalyst. Finally, alkyne-PEG-acetylene was bonded to the 
resulting PLA-PS-N3 using CuAAC click reaction. All intermediates, related 
polymers at different stages and final PS-PLA-PEG miktoarm star copolymer were 
characterized by 1H NMR, FT-IR, GPC and DP-MS analyses. Direct pyrolysis mass 
spectrometry, (DP-MS) analyses indicated that the decomposition of PS and PEG 
chains occurred almost independently.  On the other hand, hydrolysis of PLA chains 
due to the elimination of H2O during the thermal degradation of PEG, increasing the 
yields of CO2, CO and units involving unsaturation and/or crosslinked structure was 
detected. 
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KARMAŞIK BİYOMAKROMOLEKÜLLERİN TASARIMI, SENTEZİ VE 
DEĞİŞİK UYGULAMALARDA KULLANIMI 
ÖZET 
Biyobozunur polimerlerin ilk uygulamaları 1980 yıllarında görülmüştür.Biyobozunur 
polimerler dikişler, doku mühendisliği ve ilaç salım sitemleri gibi biyomedikal alana 
uyarlabilirliğinin  keşfedilmesiyle büyük önem kazanmışlardır. Fiziksel özellikleri, 
hidrolitik bozunma profilleri ve biyolojik uyumlulukları alifatik poliesterleri ve 
kopoliesterlerini biyomedikal ürünler arasında karşılaştırılamaz kadar önemli bir 
konuma getirmiştir. Ayrıca, bu polimeler çevreye zararlı olmadıklarından daha 
yakından incelenmekte olup, ‘yeşil’ olarak adlandırılmaktadırlar. En popüler 
poliesterler arasında  glikolid (GA), laktid (LA), β-bütirolakton (β-BL), ε-
kaprolactone (ε-CL) ve trimetilkarbonat (TMC) gibi malzemelerden türetilen 
polimerler yer almaktadır. Bu polimerlerin popüler olmasının en büyük sebebi, 
degredasyon ürünlerinin toksik olmayışı ve normal metabolik yollar ile elimine 
edilebilmeleridir. Bu biyopolimerlerin potansiyel uygulamaları arasında polimerik 
tanecikler ile ilaçların ya da tedavi edici ajanların taşınması yer almaktadır. Mikro- 
ya da nano- küreler gibi polimerik taşıyıcı tanecikler, zor cerrahi operasyonlar ile 
büyük implatasyon uygulamaları yerine, belirlenen bölgede ve belirli zaman 
miktarlarında istenilen ilacı salmak üzere kullanılabilirler. Polimerik taneciklerin ilaç 
salım özellikleri kullanılan polimerin degredasyonunun belirli fiziksel şartlar altında 
kontrol edilebilmektedir. Polimerlerin degrdasyonun büyük çoğunlukla kopolimer 
oranı ve molekül ağırlığına bağlı oldugu görülmüştür. Poli(L-laktik asit) (PLLA) ve 
poli(laktik-ko-glikolik asit) (PLGA) polimerleri kullanılarak gerçekleştirilen ilaç 
salımlarında, ilaç salımının genellikle ilacın difüzyonu ve polimer erozyonu ile 
gerçekleştiği görülmüştür. İlaç difüzyonu sırasında, ortamda bulunan su, polimer 
matriksinin içerisine polimer erozyonundan çok daha hızlı difüzlenir. Polimerin 
yapısında bulunan ve hidrolitik olarak kırılabilen bağlar polimer matriksinin 
içerisinde homojen olarak parçalanırlar. Bu nedenle polimerlerin ortalama molekül 
ağırlıgı homojen olarak azalır. Difüzyon yolu ile salınan ilaç sistemleri, ilacın 
konsantrayonuna bağlıdır. Polimerlerin yüzey erozyonu ile geçekleşen salımlarda, 
ortamda bulunan suyun polimer matriksi içeresine olan difüzyonu polimerin 
degredasyon hızından daha yavaştır. Buradaki degredasyon ince yüzey katmanında 
gerçekleşmektedir.  
Alifatik poliesterlerin üstün özellikleri olmasına rağmen, belirli uygulamalarda 
kullanılabilmeleri için geliştirilmeye ihtiyaçları vardır. Bu sebeple, poliesterlerin 
biyolojik uygulamalarda kullanabilirliğinin artırılması degredasyon profillerinin 
control edilebilmesiyle gerçekleştirilebilir. Degredasyon hızını etkileyen başlıca 
faktörler arasında hidrofiliklik, yüzey kimyası, morfoloji ve çapraz bağlanma yüzdesi 
bulunmaktadır. Degredasyon hızı alifatik poliesterlerin yeni polimer üniteleri ile 
kombinasyonu kullanılarak ayarlabilir. PLGA gibi biyobozunur polimerlerin ana 
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zincirine graft olarak yeni polimer ünitelerinin eklenmesi ile çeşitli özellikler 
kazandırılabilir. 
Bu tezde, çeşitli biyomedikal uygulamalarda kullanılmak üzere kompleks 
biyomakromoleküllerin dizayn ve sentezi anlatılmıştır. Bu bakış açısıyla, 
biyobozunur polimerlerin yeni segmentler ile geliştirilip, polimerlerin kimyasal 
yapısından kaynaklanan ilaç salım kontrolü, degredasyon özellikleri ve etkili tedavi 
ile ilgili sorunların giderilmesi amaçlanmıştır. Elde edilen polimerlerin hidrolitik 
degredasyon çalışmaları ayrıca mikroküre sentezine uygun olan polimerin de 
kontrollü salım çalışmaları gerçekleştirilmiştir. Tez çalışmasında elde edilen sonuçlar 
aşağıdaki gibidir: 
i. Model ilaç kullanılarak çeşitli poli(laktik-ko-glikolik asit) (PLGA) 
kopolimerinden mikroküre sentezi ve in vitro salım çalışmaları 
ii. Polistiren-g-polilaktik asit PS-g-PLLA ve polistiren-g-poli(laktik asit-ko-
glikolik asit) PS-g-PLLGA kopolimerlerinin sentezi, degredasyon çalışmaları 
ve bu kopolimerlerden elde edilen mikrokürelerin kontrollü salım çalışmaları 
iii. Poli(stiren-laktik asit- etilen glikol) miktoarm yıldız polimerinin sentezi ve 
piroliz çalışmaları 
İlk bölümde, ticari olarak bulunan çeşitli özelliklerde PLGA kopolimerleri ile farklı 
koşullarda mikroküre sentezi yapıldı. Farklı molekül ağırlıklarında ve farklı 
kopolimer oranlarına sahip polimerler kullanılarak karşılaştırmalar yapıldı. 
Sentezlenen mikrokürelerin yüzey karakterizasyonları ve kontrollü salım çalışmaları 
gerçekleştirildi. Bu çalışmada, sonraki aşamalarda  kullanılmak üzere metod 
geliştirme amaçladıgından ticari olarak bulunan PLGA kopolimeri kullanıldı. 
Mikroküre sentezlerinde model ilaç olarak kraniofrangenom tumorünü damarlanmayı 
azaltarak inhibe edici özelliği bulunan  imatinib mesilat kullanıldı. Mikroküreler çift 
emisyon/solvent uçurma yöntemi kullanılarak sentezlendi. Gerçekleştirilen çalışmada 
seksen farklı mikroküre sentezlendi.  Kullanılan metodun ilaç enkapsülasyonu, 
kontrollü salım çalışmaları ve mikrokürelerin yüzeyindeki etkisi araştırıldı. Salım 
çalışmaları 37˚C’de fosfat tampon çözeltisinde  (pH: 7.4) gerçekleştirildi. Salım 
çalışmaları yüksek basınç sıvı kromatografisi  (HPLC) ile takip edildi. 
Mikrokürelerin yüzey görüntüleri ise taramalı elektron mikroskopu (SEM) ile alındı.  
In vivo deneyleri için optimize edilen mikroküreler seçildi. Gerçekleştirlen deneyler 
sonucunda, biyobozunur polimerlerden elde edilen mikrokürelerin tedavi amaçlı 
lokal salım çalışmaları için uygun olabileceği görülmüştür. 
İkinci bölümde, ticari biyobozunur polimerin ile karşılaşılan sorunları gidermek 
amacıyla PLLA ve PLLGA içeren polistiren sentezi gerçekleştirlmiştir. Elde edilen 
polimerlerin hidrolitik degredasyon ve kontrollü salım çalışmaları 
gerçekleştirilmiştir. Sentezlenen polimerlerden elde edilen mikrokürelerin yüzey 
incelemeleri SEM ile gerçekleştirlmiştir. Kopolimerler nitroksit aracılıklı radikal 
polimerizasyonu, halka açılma polimerizasyonu ve klik reaksiyonun kombinasyonu 
ile sentezlenmiştir. Öncelikle klik reaksiyonu için azio fonksiyonu içeren polistiren 
(PS-N3), stiren ve klorometil stiren ile nitroksit aracılıklı radikal polimerizasyonu 
kullanılarak sentezlendikten sonra NaN3 varlıgında klor grupları azid fonksiyonu ile 
yer değiştirmesi ile elde edilmiştir. Propargil fonksiyonlu alifatik poliester sentezi 
halka açılma reaksiyonu ile propargil alkolün başlatıcı olduğu reaksiyon ile 130˚C’de 
sentezlenmiştir. Son aşamda, PS-N3 ve propargil fonksiyonlu alifatik polieseterler 
klik reaksiyonu kullanılarak graft kopolimerler elde edilmiştir. Elde edilen graft 
kopolimer ve ara basamaklarda sentezlenen polimerlerin 1H-NMR, FT-IR ve GPC 
kullanılar karakterizasyonu yapılmıştır. Graft kopolimerlerin hidrolitik degredasyon 
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çalışmaları 37˚C’de fosfat tampon çözeltisinde moleküler ağırlıklarındaki azalma 
takip edilerek  gerçekleştirilmiştir. Elde edilen sonuçlar  her iki polimerinde 
degredasyona uğradıklarını fakat PS-g-PLLGA kopolimerinin içerdiği hidrofilik 
glikolit ünitelerinden dolayı daha hızlı degrede olduğunu göstermektedir. Kontrollü 
salım sonuçları ise, graft kopolimerlerinin yapısında bulunan polistiren ana zincirinin 
degredasyonu yavaşlatmasından dolayı daha iyi kontrol sağlandığını ve salım 
zamanını uzattığını göstermiştir. 
Son bölümde, PS-PLA-PEG miktoarm yıldız polimerinin sentezi ve piroliz 
çalışmaları gerçekleştirlmiştir. Polistiren, poli(laktik asit) ve poly(etilen glikol) 
içeren yildiz polimer sentezi atom transfer radikal polimerizasyonu ve iki ayrı klik 
reaksiyonu ve halka açılma reaksiyonu kullanılarak sentezlenmiştir. Bu amaçla, 
polimerin çekirdek kısmı olan allil ve azid fonksiyonları içeren 1-(allyloxy)-3-
azidopropan-2-ol iki aşamada sentezlenmiştir. Daha sonra kliklenebilen polimerler 
olan tiol ile azid fonksiyonlandırılmış poli(etilen glikol) ayrı olarak sentezlendi. İlk 
aşamada, tiol fonksiyonlu polistiren klik rekasiyonu ile çekirdek üzerine bağlandı. 
İkinci kol olan poli(laktik asit) ise elde edilen polimeri başlatıcı olarak kullanılarak 
halka açılma reaksiyonu ile sentezlenmiştir. Son aşamada ise azid içeren poli(etilen 
glikol) klik reaksiyonu ile iki kollu çekirdeğe bağlanmıştır. Elde edilen graft 
kopolimer ve ara basamaklarda sentezlenen polimerlerin 1H-NMR, FT-IR ve GPC 
kullanılar karakterizasyonu yapılmıştır. Direkt piroliz kütle spektroskopsi ile termal 
analizleri gerçekleştirldi. PEG polimerinin degredasyonu sonunca açığa çıkan 
H2O’nun PLA polimerinin degredasyonunu hızlandırdığı görülmüştür. 
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1. INTRODUCTION 
Biodegradable polymers were first introduced in 1980s [1]. These polymers have 
gained much attention since the discovery of their feasibility to biomedical 
applications such as sutures, bone screws, tissue engineering scaffolds and drug 
delivery systems [2, 3]. Generally, aliphatic polyesters are known to be 
biodegradable polymers which derived from glycolide (GA), lactide (LA), β-
butyrolactone (β-BL), ε-caprolactone (ε-CL), and trimethylcarbonate (TMC). 
Aliphatic polyesters can be synthesized in three major routes such as poly 
condensation, ring-opening polymerization and enzymatic polymerization. The most 
common way of synthesis is the ring-opening polymrerization which leads high 
molecular weight polymers. The popularity of aliphatic polyesters depends on their 
resorbability and good mechanical properties. Also, Food and Drug Administration 
(FDA) have approved the usage of these aliphatic polyesters [4]. Despite their 
superior properties, they are still need to be improved. Degradation is the main 
feature of these polymers in general applications. Degradation mechanisms of 
biodegradable polymers can be categorized as hydrolytic and/or microbial routes [5]. 
The degradation processes occur by the cleavage of the backbone ester linkages of 
polymers. Hydrophilicity, surface chemistry, morphology and crosslink density are 
major factors that influences degradation rate [6].  Although aliphatic polyesters have 
been used for many years for biomedical and pharmaceutical applications are not 
good enough for certain applications such as those involving drug delivery devices 
and implant systems. The basic approach behind the utilization of aliphatic 
polyesters in biomedical field is the controlling the degradation behavior of the 
polymers. Recently, many studies have focused on block and graft copolymers in 
biomedical applications [7]. It is well known that the modification of the chemical 
structure of a polymer may lead to improvements in both physico-chemical and drug 
release properties[8]. Grafted copolymers not only have different architectures to 
linear polymers, but also different chemical and physical properties. 
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1.1 Purpose of the Thesis 
The main subject of this thesis is to synthesize new biodegradable polymers for 
various applications in biomedical field. Additionally, controlled release profiles and 
hydrolytic degradation behaviors of suitable polymers for microsphere preparation 
among the synthesized polymers and common biodegradable polyesters are also 
studied. 
This thesis also focuses on introducing new segments to common biodegradable 
polymers to overcome the common problems associated with the chemical 
composition of the biodegradable polymers such as the control of drug release, 
degradation behavior and effective treatment. 
In this respect, we firstly aimed to prepare microspheres made of commercial 
biodegradable polymers at different conditions. Polymers with a different molecular 
weights and compositions are used for comparison. Surface characteristics and 
controlled release profiles of synthesized microspheres are examined. 
Secondly, new copolymers of commercial biopolymers are synthesized. These 
include polystyrene-g-poly (lactic acid) (PS-g-PLLA) and polystyrene-g-poly(lactic-
co-glycolic acid) PS-g-PLLGA. Suitability of the synthesized polymers for 
microsphere preparation is also investigated. Controlled release studies are 
performed to confirm hydrolytic degradation profiles and prolonged release times.   
Finally, a new ABC type miktoarm star copolymer possessing polystyrene (PS), 
poly(lactic acid) (PLA) and poly(ethylene glycol) (PEG) arms was synthesized. PLA 
and PEG segments compose biodegradable and biologically manageable parts of the 
polymer. Thermal degradation studies are performed in order to obtain information 
for future applications of the polymer in biomedical field. 
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2. THEORETICAL PART 
2.1 Biodegradable Polymers 
The use of polymeric materials for administration of pharmaceuticals as drug 
delivery devices generated a continuously growing amount of interest. Biodegradable 
polymers are of special interest because they do not accumulate in nor harm the 
environment and thus can be considered “green” [9]. A wide range of applications of 
biodegradable polymers exist including pharmacological uses, mechanical support, 
mechanical barrier and carriers to cells with or without targeting [10]. Biodegradable 
polymers are preferred as drug carriers since the need for surgical removal of the 
depleted device is eliminated [11]. The important properties that are required for 
biodegradable biomaterials can be summarized as follows [12-14]:  
• Nontoxic and endotoxin - free, aiming to minimalize unwanted foreign body 
responses upon implantation. 
• Degradation time should be matched to the regeneration or required therapy 
   time. 
• Mechanical properties must be suited to the required task. 
• Degradation products should be nontoxic and readily cleared from the body. 
• Material must be easily processed to allow tailoring for the required task. 
Although there is variety of biodegradable polymers, only a limited number of 
polymers elicit the requirements for drug delivery. Biodegradable polymers can be 
either natural or synthetic. In general, synthetic polymers offer greater advantages 
over natural ones as they can be tailored to give a wider range of possibilities with a 
variety of properties [15]. The natural polymers consist of polysaccharides, dextran 
or cellulose, chitin, chitosan and proteins [16-21]. Synthetic degradable polymers 
include aliphatic polyesters, polyanhydrites, aliphatic polycarbonates and poly 
(ortho) esters [22-30]. Thermal and mechanical properties of polyesters shown in 
Table 2.1 [31]. 
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Table 2. 1: Thermal and mechanical properties of biodegradable polyesters. 
Polymer Mw 
Tg 
(°C) 
Tm 
(°C) 
Tensile 
Strength 
(MPa) 
Elongation 
Yield(%) Break (%) 
Poly(lactic acid)       
L-PLA 50,000 54 170 28 3.7 6.0 
L-PLA 100,000 58 159 50 2.6 3.3 
L-PLA 300,000 59 178 48 1.8 2.0 
DL-PLA 107,000 51 - 29 4.0 5.0 
Poly(glycolic acid)       
PGA 50,000 35 210 NA NA NA 
Poly(3-
hydroxybutyrate) 
      
PHB 370,000 9 171 36 2.2 2.5 
Polycaprolactone       
PCL 44,000 -62 57 16 7.0 80 
Poly(trimethylene 
carbonate) 
      
PTC 48,000 -15 - 0.5 20 160 
 
2.1.1 Aliphatic polyesters 
The first report of aliphatic polyesters dates back as early as 1930 [32]. 
Biodegradable aliphatic polyesters, which are in principle degradable hydrolytically, 
are by far the most employed. Generally, polyesters with short aliphatic chains 
between ester linkages, poly(hydroxycarboxylic acid)s, degrade slower than expected 
for a biomedical use. Polymers obtained from the ring opening polymerization 
reaction of lactones or cyclic diesters compose the major group of 
poly(hydroxycarboxylic acid)s. This polymerization process has been up-graded to 
the industrial production of PLA and poly(ε-caprolactone) (PCL). It is worth noting 
that polylactide can be made available from agricultural renewable resources. 
Contamination of the aliphatic polyesters by potentially toxic metallic residues is a 
concern for many applications, particularly for biomedical applications. In order to 
alleviate this problem, organometallic initiators have been successfully replaced by 
lipases and full organic systems. Another source of poly(hydroxycarboxylic acid)s is 
poly(hydroxyalkonoate)s (PHA) produced by bacteria. Polyesters can be obtained by 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
5 
direct condensation of alcohols or diols and acids or diacids. Polymers with a low 
and uncontrolled molecular weight are not suitable for biomedical applications.  
Commonly, lactide, glycolide, ε-caprolactone (ε-CL), and hydroxybutyrate 
monomers are used to obtain homo- and copolymers for medical applications.  
Structures of these monomers and polymers shown in Figure 2.1.  
 
Figure 2. 1: Molecular structures of common cyclic monomers and their polymers 
2.1.1.1 Polylactide, PLA 
Lactic acid (chemically, 2-hydroxypropanoic acid, LA), also known as milk acid, is 
the most widely occurring carboxylic acid in nature. It was first isolated in 1780 by a 
Swedish chemist, Carl Wilhelm Scheele, but it was first produced commercially by 
Charles E. Avery at Littleton, Massachusetts, USA in 1881 [33].  The L-isomer 
constitutes the main fraction of PLA derived from renewable sources since the 
majority of lactic acid from biological sources exists in this form PLA belongs to the 
family of aliphatic polyesters derived from α-hydroxy acids. Biomedical use of PLA 
started at 1960s [34].  PLA gained much attention due to its good mechanical 
properties and non-toxic degradation products. PLA has been approved by FDA and 
commercially available. Lactide has two asymmetric carbons and thus exists as the 
optically active L- and D- forms or as the racemic D, L- form. Possible 
stereochemical structures of lactide are shown in Figure 2.2. 
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Figure 2. 2: Stereochemical possibilities observed with polylactide synthesis. 
Commercial PLA are homopolymer of poly(L-lactic acid) (PLLA) or copolymer of 
poly(D,L-lactic acid) (PDLLA), which are produced from L-lactic acid and D,L- 
lactic acid [33].  PLA can be synthesized by polycondensation, azeotropic 
dehydrative polycondensation, and ring-opening polymerization (ROP) of lactide 
(Figure 2.3).  
 
Figure 2. 3: Different preparation methods of PLA. 
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By and large, commercially available high-molecular-weight PLA resins are mainly 
produced via the ring-opening polymerization route of lactide [35]. ROP of lactide 
monomer can be initiated with various compounds. Reaction mechanism of ROP 
with different initiators is shown in Figure 2.4. 
 
 
 
Figure 2. 4: Reaction mechanism of ROP with different initiators. 
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The most common used catalyst in synthesis of polylactide is aluminum 
isopropoxide. It is less reactive than stannous (II) octaoate (Sn(Oct)2) and also there 
are some suspects about the relation between aluminum ions and Alzheimer’s disease 
[36].  Stannous (II) octaoate is a commonly used catalyst in polymerization of cyclic 
lactones such as glycolide, ε-caprolactone or trimethylene carbonate [37]. Reaction 
mechanism differs between lactones. The mechanism of ROP of lactide in presence 
of stannous octaoate catalyst is shown in Figure 2.5. 
 
Figure 2.5: Hypothetical mechanism of ring-opening polymerization of lactide using 
Sn(Oct)2 as catalyst. 
Also, there are eco-friendly processes catalyzed by enzymes to produce polyesters 
[38]. Enzyme catalyzed reactions has benefits like elimination of side reactions and 
regio- and steriospecificticy [39]. 
 PLLA has  crystalline melting temperature (Tc) range between 170-180 ˚C due to its 
sterioregular structure and glass transition temperature (Tg) of PLLA is about 60-
67˚C [40]. Racemic PLA is purely amorphous instead of PLLA which affects the 
biodegradation of polymers. Crystallinity is an important factor on biodegradation. 
However, unitary structure and poor properties of PLLA such as the inherent 
brittleness, poor melt strength, low heat deflection temperature, narrow processing 
window and low thermal stability have posed considerable scientific challenges and 
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limited their large-scale applications. The most common strategy to overcome this 
limit is to prepare the copolymers. Copolymerization of lactic acid (or lactide) with 
hydroxyl acid, amino acid or polymers such as PEG, starch, etc., can markedly 
improve the strength, toughness, hydrophilic and controlled degradable properties of 
PLA, and at the same time numerous new copolymers in different macromolecular 
architectures (linear, branch, star and dendron) can be obtained [41]. These materials 
are attracting considerable interest in materials science research. In the past several 
decades, extensive work has been carried out to synthesize the desired PLA 
copolymers for drug delivery, hydrogels, nanoparticles, microparticles, implants, 
micelles, etc. PLA copolymers can be synthesized by several kinds of well-known 
polymerization techniques, including polycondensation, anionic, cationic, and 
coordination-insertion ring-opening polymerization [42]. Copolymers of PLA with 
different cyclic esters such as glycolide, ε- caprolactone, ε- decaloactone or and 
blends of PLA with various polymers like PEG, alginate or chitin are highly 
noteworthy materials especially for drug delivery applications [42, 43].  PLA has 
been used in systematic delivery of several therapeutic agents such as contraceptive 
steroids, narcotic antagonists, antimalarial agents etc. [44-46]. Delivery of proteins 
from microspheres prepared from PLLA and PDLLA have also been reported [47]. 
2.1.1.2 Polyglycolide, PGA 
PGA is a linear, biodegradable and thermoplastic polymer. It is mostly prepared by 
ring-opening polymerization of glycolide. Owing to crystalline structure, PGA has 
Tm about 225 ˚C and Tg of 36 ˚C [48]. Its hydrolytic instability and insolubility in 
common organic solvents have limited the usage of the polymer. However, PGA has 
an excellent fiber-forming property that is commercialized as the first absorbable 
suture in 1970 [48]. Copolymers of PGA are generally preferred for drug delivery 
applications depending on the deficiencies of the polymer that it cannot be made into 
films, capsules or microspheres.  
2.1.1.3 Poly(lactide-co-glycolide), PLGA 
Copolymers of lactide/glycolide monomers have received the most attention in 
recent years. PLGA ows its popularity to its, degradation profile, non-toxic 
degradation products, ease of preparation and commercially avalibity. Composition 
of LA and GA units determine the hydrophiliciy and crystallinity of the copolymer. 
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As GA units increase in the polymer composition, hydrophilicity of the polymer 
increases. Increasing number of GA units lead higher degradation rates. Linear 
lactide- and glycolide-based polymers are most commonly synthesized by ring-
opening melt polymerization of lactide and glycolide at 140–180°C for 2–10 h using 
a catalyst [49]. Extensive research has been devoted to the use of these polymers as 
carriers for controlled drug delivery of a wide range of bioactive agents for human 
and animal use [50]. 
2.1.1.4 Poly(ε-caprolactone), PCL 
The successful use of lactide and glycolide polymers in absorbable drug delivery 
systems and medical devices and absorbable sutures encouraged the evaluation of 
other polyesters for this purpose. The most studied polymers in this category are the 
PCLs. PCL is also a biodegradable and harmless material. PCL is a semi-crystalline 
and hydrophobic polymer with fine non-polar methylene groups in its repeating unit 
[51]. Different routes can be followed to synthesize PCL such as anionic, cationic, 
coordination, radical and enzyme catalyzed polymerizations shown in Figure 2.6 
[11].  
 
Figure 2. 6: Polymerization of ε-caprolactone using (a) anionic, (b) cationic, (c)      
coordination catalysts. 
Most common way of synthesizing PCL is ring-opening polymerization of ε-
caprolactone monomer shown in Figure 2.7 [52]. 
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Figure 2.7: Synthesis of PCL in the presence of stannous octaoate; (a,b) formation of 
stannous alkoxide, (c) deactivation of the catalyst by reaction of water, 
(d) coordination/insertion of monomer into the stannous alkoxide bond 
generating dimer, (e) chain transfer of the active polymerizing center. 
The homopolymer melts at 59–64°C with a Tg of -60°C [53]. PCL has slower 
degradation rate than PLA and PLGA. Degradation of PCL and its copolymers 
occurs both in vivo and in vitro conditions by bulk hydrolysis like lactide polymers. 
Degradation of PCL proceeds through hydrolysis of ester linkages at the backbone of 
the polymer which yields 6-hydroycaproic acid that enters the citric acid cycle and 
completely metabolized [11]. Degradation rate of PCL can be adjusted by 
copolymerization of lactide or glycolide monomers. Also, addition of oleic acid or 
tertiary amines which catalyses the chain hydrolysis may increase the degradation 
rate of PCLs. 
There are many approaches to combine properties of PCL with other biodegradable 
polymers to provide desired needs in biomedical field [54]. Copolymers of PCL with 
glycolides or lactides and blends with PEG, polyhydroxybutyrates (PHB) or 
poly(mandelic acid) have been prepared to fabricate microspheres for drug delivery 
systems [55].  
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2.1.1.5 Poly(3-hydroxybutyrate), (PHB) 
The most common polymer derived from bacteria is poly(3-hydroxybutyrate). PHB 
first isolated and characterized in 1925 by Indian microbiologist Abhilash Singh 
[56].  PHB produced by controlled bacterial fermentation. An optically active 
polymer of 3-hydroxybutyrate has been produced from propionic acid or pentanoic 
acid by Alcaligeneseutrophus [57]. Molecular structure of 3-hydroxybutyrate is 
shown in Figure 2.8. 
 
Figure 2. 8: 3-Hydroxy butyrate. 
PHB has attracted much attention because they are produced biosynthetically from 
renewable sources and biocompatible. Copolymers of PHB with different monomers 
have been demonstrated but poor resistance to acids and bases limits modification of 
the polymer [56].  
PHB can replace synthetic polymers due to similar properties with an advantage of 
being completely biodegradable. Mechanical and thermoplastic properties of PHB 
are similar to polypropylene.  PHB is non-toxic material with properties like good 
oxygen permeability and ultra-violet resistance but poor resistance to acids and 
bases. PHB is characterized as having a high molecular weight with a narrow 
polydispersity and a crystallinity of around 50%. Depending on the crystallinity, 
PHB has the melting point of 171°C with a Tg at 9°C. PHBs are water insoluble and 
relatively resistant to hydrolytic degradation [58]. In vitro hydrolytic degradation of 
microspheres made of PHB degradated about 20-40% after 5 months at 85˚C which 
is very long time for a biodegradable polymer [59]. The factors affect the 
biodegradability of PHB depend on the characteristics of PHB such as 
stereospecificity, crystallinity, molecular weight and monomeric composition. 
Stereospecificity has influence on degradation because only monomers are in R 
configuration are hydrolyzed by depolymerases. High degree of crystallinity and 
high molecular weights of the polymers result in lower degradation rates. 
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PHBs are getting popular with biodegradability, mechanical and physical properties. 
The major disadvantage of the PHB is high production cost. Researches on 
production of PHB from cheap raw materials are still in progress. 
2.1.2 Polyanhydrides, (PA)s 
Polyanhydrides were synthesized by Bucher and Slade in 1909 but first utilization of 
PAs for controlled drug delivery was in 1980 [60].  But today, PAs have been used in 
various forms to deliver diverse active agents and other biomedical applications. PAs 
can be synthesized with different specific properties such as crystallinity, degradation 
behavior, crosslinking or branching etc.  A broad variety of PAs has been 
synthesized over years, based on one or a combination of aliphatic, aromatic, and 
heterocyclic monomers [61]. There are various kinds of polyanhyrides depending on 
the monomer type. Some examples of PAs are shown in Table 2.2.  
Table 2. 2: Molecular structures of common polyanhydrides. 
Main 
Structure 
R 
Group 
Structure of 
R Group 
 
 
n = 4, adipic acid 
n = 6, suberic acid  
 
 
p-
Carboxyphenoxypr
opan 
 
 
 
 
Fumaric acid (FA) 
 
 
 
Terepthalic acid 
(TA) 
 
 
 
Isopthalic acid 
(IPA) 
 
 
 
Fatty acid dimer 
(FAD) 
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Several techniques exist in literature to synthesize polyanhydrides such as melt 
condensation, ROP, interfacial condensation, dehydrochlorination, and dehydrative 
Coupling agents shown in Figure 2.9 [62]. 
 
Figure 2. 9: General synthesis schemes of polyanhydrides. 
The common way of synthesizing PAs is melt polycondensation. A dicaboxylic acid 
is refluxed with an excess of acetic acid anhydride yielding a solution of mixed 
anhydride. The excess acetic anhydride is removed in vacuum at high temperatures, 
resulting in high polyanhydrides [63]. Also, photo initiated thiol-ene chemistry can 
successfully be used to obtain linear and crosslinked polyanhyrides [64]. Many kinds 
of catalysts can be used in PA synthesis varying by the type of the techniques. 
Many polyanhyrides have low melting points and are soluble in common organic 
solvents.  Some PAs are nontoxic and degrade finally into diacids which are either 
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excreted as such in feces/urine or undergo extensive metabolism to form carbon 
dioxide and water in the body.  
Surface erosion is an important issue to control over release. Expectation from a 
surface eroding polymeric carrier is releasing drug at a constant rate which is 
proportional to surface eroding rate of the polymer. The polymer should have water 
labile linkages but should be hydrophobic. PAs are believed to predominantly 
undergo surface erosion due to the high water lability of the anhydride bonds on the 
surface and hydrophobicity, which restricts water penetration into the bulk [65]. pH 
of the surrounding media is important on hydrolytic degradation of polyanhydrides 
due to nature of base catalyzed anhydride bond. High hydrolytic reactivity of the 
anhydride linkage provides an intrinsic advantage in versatility and control of 
degradation rates. By varying the type of monomer and their ratios, surface - eroding 
polymers with degradation times of 1 week to several years can be designed and 
synthesized. 
2.1.3 Aliphatic polycarbonates 
Aliphatic polycarbonates gained much attention owing to their restorability and they 
are used as polymeric additives for plasticizing properties [66]. Polycarbonates are 
linear thermoplastic polymers of carbonic acid and aliphatic dihydroxy compounds. 
Aliphatic polycarbonates can be synthesized from the reaction of dihydroxy 
compounds with phosgene or bischloroformates of aliphatic dihydroxy compounds 
by transesterificaiton and ring-opening polymerization of  cyclic carbonates, 
commonly 5 or 6 membered ring monomers [66]. Suggesting that the carbonate bond 
may be labile to hydrolysis a biodegradation study is performed [67]. According to in 
vivo studies of poly(ethylene carbonate) and poly(propylene carbonate) a weight loss 
of polymer pellets is monitored. But in vitro studies showed that of poly(ethylene 
carbonate) completely depredated in 15 days while  poly(propylene carbonate) 
pellets did not degradade even after an incubation of 40 days in PBS with pH 7.4 at 
37˚C. Monitoring a weight loss as a result of degradation of poly(propylene 
carbonate) pellets in in vivo studies while there is no change  in in vitro researches 
indicate that, the polymer pellet was degraded by enzymes [67]. 
Copolymer of aliphatic polycarbonates and lactides showed excellent mechanical 
properties and biocompability. Especially, poly(trimethylene carbonate), (PTMC), 
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had been investigated in biomedical applications shown in Figure 1. PTMC has low 
Tg of -17 ˚C and it stays rubbery at room temperature. Degradation of PTMC occurs 
by both hydrolysis and enzymatically [68]. Polycarbonate bond is more sensitive 
than polyester linkage but PTMC hydrolyses very slowly due to lack of an 
autocatalytic process. Total degradation of PTMC may take years [69]. Degradation 
products of PTMC are carbon dioxide and diols. Copolymers of PTMC with various 
polymers have been reported to be useful matrix for biomedical applications [70]. 
2.1.4 Poly(orthoester)s, POE 
Poly(orthoester)s developed to meet the needs for an ideal biodegradable polymer 
such as surface erosion, non-toxic degradation products with low molecular weight 
and controllable degradation rate. Erosion on the surface should be faster than 
interior part of the particle to control the degradation rate by surface erosion. 
Degradation rate slowly increases as the pH of the surrounding medium decreases 
due to the orthoester linkage. Polymeric carriers made of POEs which has a sensitive 
bond to acids may be successful if the interior part of the carrier buffered by basic 
salts. Poly(orthoesters) are divided into four different classes shown in Fig. 2.10. 
 
 
Figure 2. 10: Classes of poly(orthoester)s 
POE 1 was first synthesized by ALZA Corporation in 1970s [71]. POE 1 undergoes 
an autocatalytzed and uncontrollable hydrolysis as a consequence of acid labile 
natures. First hydrolysis product of POE1 is butyrolactone which finally hydrolysis 
into butyric acid shown in Figure 2.11.  
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Figure 2. 11: Hydrolysis of POE 1. 
Prevention of POE 1 from autocatalyzed hydrolysis a base must be added to stabilize 
the polymer. Poor mechanical properties, difficulties in synthesis and uncontrollable 
hydrolysis of POE 1, blocked the commercialization of the polymer and therefore 
POE 1 is no longer under investigation. 
Researches on POE 2 showed that the polymer has high biocompability with great 
drug release profile [72]. Nevertheless, being unrepeatable in synthesis and 
difficulties in scaling up the reaction also limited the commercialization of the 
polymer [72].  
In spite of problems faced in POE 1 and POE 2, the other two structures POE 3 and 
POE 4 are quite successful. For instance, POE 4 has completed Phase 2 and Phase 3 
clinical trials on delivery of granisetron and mepivacaine, respectively. [73]. 
Extensive researches on POE 3 are still ongoing [73]. 
POE 3 
POE 3 can be obtained by the reaction of diketene acetal with 3,9 diethylidene-
2,4,8,10 - tetraoxaspiro undecane as shown in Figure 2.12  [73].   
 
 
Figure 2. 12: Synthesis of POE 3. 
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But the 3, 9 diethylidene-2, 4,8,10 - tetraoxaspiro undecane is not commercially 
available. It must be synthesized individually by the rearrangement of diallyl 
pentaerytritol as shown in Figure 2.13 [73]. 
 
Figure 2.13: Synthesis of 3, 9 diethylidene-2, 4,8,10 - tetraoxaspiro undecane 
(DETOSU). 
Instead being very labile in aqueous environment, the nature of the polymer is 
hydrophobic. Because of this reason hydophilicity of the polymer must be adjusted to 
control the surface erosion rate of the polymer.  
POE 4 
Development of POE 4 is consequence of uncontrollable surface erosion of POE 3. 
POE 4 can be obtained from the reaction of the diketene acetal, 9 diethylidene-2, 
4,8,10-tetraoxaspiro undecane, a diol or mixture of diols with latent acid diol as 
shown in Figure 2.14 [73]. 
 
Figure 2. 14: Synthesis of POE 4. 
Latent acid is used to control the surface erosion rate by α-hydroxy acid segments. 
Latent acid is synthesized from the reaction between a diol and ether lactide or 
glycolide as shown in Figure 2.15 [73] 
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Figure 2. 15: Synthesis of latent acid based on lactide. 
Having various diols at preparation stage, gives the opportunity to synthesize 
polymers with a wide range of different physical properties. A mixture of rigid diol 
and flexible diol can be used to control the mechanical properties of the polymer. 
2.1.5 Poly(ethylene glycol), PEG 
Poly(ethylene glycol) contains ether linkages in repeating units of the polymer which 
has many application fields differ from industrial manufacturing to medicine. PEG is 
a hydrophilic, non-ionic polymer with excellent biocompability which also approved 
by FDA.  It has also been known as poly(ethylene oxide) or poly(oxy ethylene) 
depending on its  molecular weight. The trade name for PEG is Carbowax [74]. The 
polymers with a molecular weight below 20.000g/mol is called as PEG where 
polymers with a molecular weight above 20.000g/mol is called as poly(ethylene 
oxide) (POE). Poly(oxy ethylene) is used for  any molecular weight. PEGs are 
synthesized from the reaction of ethylene oxide with water, ethylene glycol or 
ethylene glycol oligomers and commercially available over a wide range of 
molecular weights [75]. Ethylene glycol or ethylene glycol oligomers are preferable 
against water because the capability of producing polymers with low polydispersity. 
The reaction is generally catalyzed by acidic or basic reactants. Figure 2.16 shows 
the molecular structure of PEG [76]. 
 
Figure 2. 16: Poly(ethylene glycol). 
The catalyst type determines the kind of polymerization that can be either anionic or 
cationic. Anionic type of polymerization leads producing PEG with low 
polydispersity. POEs are produced by suspension polymerization where magnesium-
aluminum-, or calcium-organoelement compounds used as catalyst [77]. Chelating 
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additives such as dimethylglyoxime are used to prevent coagulation of polymer chain 
from solution. 
 PEG and POE are liquids or low-melting materials. The chemical properties of these 
polymers are nearly identical. Applications of PEG and POE change due to different 
physical properties due to chain length effects. PEG and POE can used as non-ionic 
surfactants, coupling agent, humectants, lubricants in cosmetics, antifoams, seal 
lubricants, plasticizer to increase the lubricity, cryogenic fluids, anti-dusting agents 
in agricultural formulations, dye carriers in paint and inks, softener and anti-static 
agent for textiles, and etc.  Many different forms of PEG exist dependent on the 
initiator used in polymerization [78]. The most common example is monofunctional 
PEG which is called methoxypoly(ethylene glycol) (mPEG).   
PEG with a molecular weight about 1000g/mol is a crystalline, linear polymer. The 
crystalline melting point of the polymer increases with molecular weight. PEGs and 
copolymers with high PEG content are generally water soluble. 
PEG has variety of usage areas in biomedical applications according to non-toxicity 
and solubility in water. For instance, when PEG is attached to protein medications 
the polymer slows the clearance of the carried protein from the blood [79]. It allows 
longer dosing intervals. Another commercialized example of the polymer is PEG-
interferon alpha which is used to treat hepatitis C. Also, PEG-filgrastim is used to 
treat neutropenia. The most common usage of PEG is fusing B-cells with myeloma 
cells in monoclonal antibody production [80]. Copolymers and blends of PEG are 
used in fabrication of microspheres for controlled drug delivery applications where 
PEG is used to control the release rate of the drugs by the degradation of polymers 
[81].  
2.2 Polymer Degradation and Erosion 
Degradation of the biodegradable polymers is as important as their synthesis and 
properties, in biomedical applications. The polymer must perform its duty while 
degradation occurs in a predictable way. Degradation products of the polymer must 
be non-toxic and must have no harm to the other organs or organ functions.  Polymer 
degradation is a change in the properties of polymer like tensile strength, color, shape 
etc. by chemical reactions resulting in a cleavage of main chain bonds.  Generally, 
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polymer degradation begins with hydrolytic and/or enzymatic attack which results in 
shorter oligomers, monomers and low molecular weight products [11]. If the 
degradation occurs via environmental action, bacteria or enzymes it is called 
biodegradation or biotic degradation and polymer is considered as biodegradable 
polymer [11-82].  
Bulk and surface erosion are two different mechanisms discussed in the literature for 
biodegradation [83]. In the bulk degradation process, water diffuses into the polymer 
matrix faster than the polymer is degraded. The hydrolysable bonds in the whole 
polymer matrix are cleaved homogeneously. Therefore, the average molecular 
weight of the polymer decreases homogeneously. Release of the drug occurs by 
diffusion which is related to concentration of the drug. The bulk degradation process 
is shown in Figure 2.17. In the case of surface erosion, the diffusion rate of water 
into the polymer matrix is slower than the degradation rate of the macromolecules. 
The degradation only takes place in the thin surface layer while the molecular weight 
of the polymer in the bulk remains unchanged. Surface erosion is a heterogeneous 
process, with a rate strongly dependent on the shape of the test sample [84]. The 
surface erosion is shown in Figure 2.18. But achieving surface erosion is difficult. 
Generally, biodegradable polymers are not hydrophobic enough to keep water from 
penetrating into material to let the surface layer to erode [85]. Release of the drug 
occurs in zero-order fashion by surface erosion.  
 
Figure 2. 17: Bulk erosion of a degradable polymer. 
 
Figure 2. 18: Surface erosion of a degradable polymer. 
Erosion rates can be determined in vitro and in vivo [84]. For in vitro experiments, 
the polymers are exposed to an aqueous solution, in which ionic strength, pH-value, 
and temperature can be varied.  Additionally, polymers can be tested on cell and 
tissue cultures. Determination of the degradation behavior of polymers under suitable 
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conditions for in vivo experiments gives information on the compatibility of the 
partially degraded polymer samples and their degradation products. 
Chemical structure, molecular weight and polydispersity, crytallinity, water 
solubility and permeability, mechanism of hydrolysis, method of chain scission, 
morphology of the polymeric carrier, porosity, method of sterilization and site of 
application are known as main factors that affect degradation and the life time of 
biopolymers [11]. The most important parameter of the degradation is chemical 
structure and hyrophilicity/hyrdphobicity of the polymer [85]. Hydrophilic polymers 
are known as bulk-degrading polymers where surrounding aqueous media diffuses 
into polymer matrix. Polymers made of hydrophobic backbone with hydrolytically 
non-labile linkages are very slow degradating polymers but polymers synthesized 
from hydrophobic monomers having labile bonds which do not allow the penetration 
of water but erodes from the surface are called surface-degrading polymers. Mass 
loss of surface-degrading polymers does not change significantly because the 
monomer is so hydrophobic that they do not diffuse into the surrounding medium. 
Natural polymers are generally hydrophilic and undergo bulk degradation and 
enzymatic degradation [86]. A few synthetic polymers undergo enzymatic 
degradation such as polyesters. Instead of hyrophlicity of the polymers, solubility of 
the degradation product is an important issue, too. Lower molecular weight of the 
degradation products with higher aqueous solubility result in faster degradation and 
easier evacuation from the body. Some of the by-products of degradation are 
hydrophobic, as in the case of polyanhydrides, make the degradation slow and 
accumulate on the polymer matrix [86]. Another situation caused by the degradation 
products is auto catalytic effect. The catalytic effect usually occurs by the pH change 
of the surrounding medium because of the degradation products. Free radical 
production during degradation sometimes causes chain scission in some polymers. 
Having high number of molecular weight distribution increases the degradation rate 
where there are more groups to accelerate the chain scission that lead faster 
degradation of the polymer. A few polymers exist with completely crystalline 
structure as they degrade compared to their amorphous analogues. Molecular 
arrangement of crystalline polymers does not allow water to penetrate into polymer 
matrix due to higher lattice energy [86].   
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Glass transition temperature has an influence on degradation of amorphous 
structures. Polymers with higher Tg, degredates slower in the same class of polymers 
due to increasing molecular weight. Also, Tg is the proof of that, the molecule is 
stable in particular molecular configuration which may cause the hydrophobic 
interaction resulting in slower degradation rate. 
As the size of the polymeric carrier increases, the time is required for complete 
degradation increases. The effect of increase in the size of device is more clearly 
seen in surface-degrading polymers than bulk-degrading polymers as the degradation 
takes place throughout the matrix [87]. 
Porosity changes the surface-to-volume ratio which affect the degradation rate by the 
increase in the surface area inturn exposes more surfaces to the hydrolytic media 
results in faster degradation rate [88]. 
Drug containing additives, may change the degradation rate of the polymer by 
affecting the polymer due to the hydrophilicity/hydrophobicity of the drug [89]. 
Processing the polymer during sterilization or modification, physical or chemical 
structure may be affected. Any change in chemical structure of the polymer affects 
further degradation profile [90]. 
Location or site of the drug affects degradation by blood flow, movement of the 
device or loading of the device. If the environment where the polymeric carrier exists 
causes faster removal of the drug, degradation of the polymer increases if 
degradation occurs via surface eroding.  
2.3 Controlled Drug Delivery 
Several routes of administration of drugs exist such as tablets, injections etc. Entire 
dose of drug administers by this way which plasma concentration of drug sometimes 
close to toxic [91]. The therapeutic effect cannot be achieved by only administration 
of drug just once. Prolonged drug delivery system is needed to control the plasma 
concentration of drugs to overcome this problem. Releasing the drug in controlled 
fashion should provide the drug only where and when it is needed for long periods of 
time. Figure 2.19 shows the therapeutic effect as the plasma concentration of drug as 
a function of time after administration of drug.  
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Figure 2. 19: ( ) traditional delivery system, ( ) prolonged delivery 
system. 
Controlled release systems must be able to carry required amount of drug needed to 
treat the tumor, deliver the drug within a specific period of time and must be 
biocompatible. Controlled release systems vary by administration route and drug 
release mechanism. For instance diffusion controlled membranes which a reservoir 
encapsulates all drug and released by rate controlling polymer matrix. Another 
example of controlled release system is cross-linked hydrophilic polymers, 
hydrogels; drug is released by diffusion from network which is insoluble in 
surrounding medium [92]. Commonly, polymeric carriers are preferred in controlled 
release systems. Polymeric carriers are biodegradable or water soluble polymer 
matrices which encapsulate drugs without any chemical bonding. The drug is 
released by degradation and erosion of the polymeric structures. Controlled release 
fashion helps to protect therapeutic agents from physiological degradation that 
peptides, proteins, enzymes and some drugs lose their activity before reaching 
targeted area. Depending on the needs, polymeric carriers can be placed to the 
targeted tissue by surgery to improve efficiency of therapeutic agents. 
2.3.1 Release of therapeutic agents 
Release of therapeutic agents depends on the erosion of the polymer, dissolution of 
drug in the surrounding tissue and diffusion of the drug from polymeric carrier [93]. 
Release rates of therapeutic agents are related to hydrophilicity, flexibility, 
crystallinity, degradation rate, molecular weight of the polymers used as carrier. 
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Also, size, shape and the porosity of the carrier affect the release mechanism. 
Properties of the drugs such as size of drug molecule, solubility in water, and 
molecular weight have influence on release kinetics, too. The relationship between 
time and the amount of drug released is proportional to the square root of time. But, 
desired drug release based on zero-order kinetics which is almost unattainable.  
2.4 Microspheres 
Microspheres have received significant amount of interest after adaptation into 
biomedical applications for regeneration of tissue, targeted delivery of drugs, 
peptides, proteins, enzymes, etc. [94, 95]. Microspheres are small particles in a range 
between 1µm and 1000µm. Microspheres which are aimed to use in biomedical 
applications should be easy to fabricate, biocompatible and biodegradable [96]. 
Figure 2.20 shows the microparticle types as drug carriers made of biodegradable 
polymers. 
 
Figure 2. 20: Polymeric micro- or nano- capsules or spheres. 
Microspheres can be prepared from natural or synthetic polymers.  For instance 
polystyrene microspheres are used in cell sorting and immunio precipitation that, 
proteins and ligands adsorb onto polystyrene make it suitable for medical 
applications [97]. The most common used microspheres are made from aliphatic 
polyesters such as PLGA, PLA, PCL, PHB, etc. 
Therapeutic agent, carriers are divided in to three groups as first-, second- and third-
generation of carriers. The first generation of carriers are 
microspheres/microcapsules which able to deliver active substances to the targeted 
area. But they have to be implanted as closely as to the site of action. These systems 
are generally used for controlled release of proteins or peptides. The second 
generation of carriers are not only release the active products to the indented area but 
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also of carrying it there after administration of general route. This group is called as 
passive carriers and includes liposomes, nanocapsules or nanaospheres. But rapidly 
removal of colloidal carriers by phagocytic cells exist in the liver and spleen limit 
their utilization. The third generation carries are capable of specific recognition of 
the target that monoclonal antibodies belong to this group.  
Table 2. 3: Definition of Different Carrier Systems. 
Generation Size Definition Examples 
First >1 μm Systems able to release a 
drug at the target site but in 
a particular type of 
administration  
Microspheres and 
microcapsules for 
controlled release of 
proteins and peptides 
 
Second <1 μm Carriers able to transport a 
drug to the target site by 
general type of 
administration 
Passive Carriers: 
Liposomes, nanoparticles, 
erythrocytes 
Active Carriers: 
Temperature or pH 
sensitive liposomes, 
magnetic nanoparticles 
 
Third <1 μm Carriers able to recognize 
the target spesifically 
Monoclonal antibodies, 
second-generation carriers 
 
Therapeutic agent release from micropheres, such as PLLA and PLGA, is generally 
controlled by both drug diffusion and polymer erosion. In the diffusion process, 
water diffuses into the polymer matrix faster than the polymer is degraded. The 
hydrolysable bonds in the whole polymer matrix are cleaved homogeneously. 
Therefore, the average molecular weight of the polymer decreases homogeneously. 
Release of the drug occurs by diffusion which is related to concentration of the drug. 
In the case of surface erosion, the diffusion rate of water into the polymer matrix is 
slower than the degradation rate of the macromolecules. The degradation only takes 
place in the thin surface layer while the molecular weight of the polymer in the bulk 
remains unchanged. 
2.4.1 Preparation methods of microspheres 
There are several techniques exist for fabrication of microspheres which affect 
characteristics of microspheres. An encapsulation technique should provide the 
following requirements [98]. 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
27 
 Microsphere production should not have any influence on stability and the 
biological activity of the drug.  
 Size of the fabricated microspheres must be <125 µm with high encapsulation 
efficiency. 
 Fabrication of microspheres and release of drug must be repeatable. 
 The microspheres should not exhibit aggregation or adherence. 
The choice of the microencapsulation technique depends on the nature of the 
polymer, usage area and the time required for the therapy. Generally solvent 
evaporation, spray dry and phase separation methods are used in preparation of 
microspheres. Solvent evaporation method is the most common technique among 
these approaches. 
2.4.1.1 Single emulsion method 
The single emulsion technique requires the emulsification of an oil phase in a 
continuous aqueous phase (o/w) or an oil phase (o/o).  The o/w method needs an 
emulsifier to obtain o/w emulsion. Poly(vinyl alcohol) (PVA) and dichloromethane 
(DCM) are relatively the most common used emulsifier and organic solvent for 
fabrication of microspheres. The emulsion (o/w) stirring speed should be reduced 
and let it at reduced pressure or atmospheric pressure for evaporation of organic 
solvent to harden the oil droplets [99]. Then, the solid microspheres obtained via 
filtration and should be dried under vacuum. There are many facts that influence the 
structure of microspheres as: 
a) structure and solubility of the drug , 
b) concentration and molecular weight of the polymer,  
c) drug/polymer ratio,  
d) choice of organic solvent, 
e) concentration and the type of surfactant,  
f) temperature, 
g) stirring speed,  
h) viscosities and volume ratios of continuous phase.  
 Solvent evaporation process is similar to the extraction method where the 
solvent must first diffuse out into the external aqueous dispersion medium before it 
could be removed by evaporation.  The rate of the solvent removal strongly affects 
the chacteristics of final microspheres which depends on the temperature, pressure 
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and the solubility parameters of the polymer. Very rapid solvent evaporation may be 
resulted in local explosion of inside the droplets and increased porosity on the 
surface of the microspheres [100]. 
A disadvantage of the singe emulsion method is poor encapsulation efficiencies of 
hydrophilic drugs. The drug would diffuse out to the continuous phase from oil 
phase. As a result, hydrophilic drugs get deposit on the microspheres which finally 
affect the release studies, initial bursts and release time of the drug.  
Steroids are generally preffered drugs for single emulsion method due to lipid 
soluble nature. 
Oil in oil technique was developed to increase encapsulation efficiencies of 
hydrophilic drugs. Oil in oil processes tend to be complex techniques requiring the 
removal of oil from final product. This method can be used to encapsulate 
hydrophobic drugs in the first oil phase. Acetonitrile is use to solubilise the 
hydrophilic drug which also solubilize the polymers intended to use. The choice of 
acetonitrile depends on the miscibility of the solvent in water. The solution consists 
of the polymer and the drug is dispersed in an oil phase such as light mineral oil in 
the presence of a surfactant [101]. Then, the microspheres obtained by evaporation or 
extraction of oil phase. At the final step the oil is removed from microspheres by 
hexane. Sometimes this method is called as water-in-oil (w/o) emulsification 
technique.  
2.4.1.2 Double emulsion method 
The double emulsion technique requires the emulsification of an aqueous solution in 
an oil phase (w/o) which is than emulsified in a continuous aqueous phase (w/o/w) 
[102]. A schematic diagram of double emulsion technique is shown in Figure 2.21. 
Double emulsion method is a proper way for encapsulation of peptides, drugs, 
proteins and vaccines which are soluble in water.  
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Figure 2. 21: A diagram of double emulsion technique. 
An aqueous or buffered solution of the drug is added to an organic phase containing 
polymer with vigorous stirring to form the first emulsion (w/o). This emulsion is 
added to large volume water containing an emulsifier to obtain w/o/w emulsion. 
Then evaporation or extraction processes take place to remove organic phase. The 
solid phase is washed and collected by filtration, sieving or centrifugation. Ethyl 
acetate, dichloromethane and hydrophilic stabilizers may be used in double emulsion 
method. Peptides, leuprolide acetate [103], a luteinizing hormone-releasing hormone 
agonist [104], vaccines, protein/peptides and conventional molecules are successfully 
encapsulated by w/o/w method. This method is popular among other preparation 
techniques owing to ease of preparation but low entrapment efficiency and high 
initial burst releases are major problems of the method. This situation may be 
attributed to water soluble drug diffusion during hardening phase of microspheres 
[105]. 
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2.4.1.3 Phase separation (Coacervation) method 
This method is carried out by reducing the solubility of polymer as consequence of 
adding the third component, such as salts or changing pH, to the organic phase which 
is a colloid phenomenon. The process yields two liquid phases: the polymer 
containing phase (coacervate) and the supernatant phase depleted in polymer. The 
drug is dissolved in the polymer solution and coated by the coacervate. The 
coacervation process includes three steps: 
1. Phase separation of the coating polymer solution 
2. Adsorption of the coacervate around drug particles 
3. Solidification of microspheres 
The polymer intended to use first dissolved in an organic solution than the drug is 
added to the organic phase if the drug is hydrophilic than aqueous solution of the 
drug is added (w/o emulsion). An organic non-solvent is added to the system with 
stirring resulting in extraction of the polymer solvent. Then, a phase separation 
occurs and soft coacervate droplets form which entrap the drug. Hardening of the 
microspheres is done by transferring the system to a large quantity of organic non-
solvent. The final microspheres are collected by filtration, sieving or centrifugation 
[106]. This method is suitable for both hydrophilic and hydrophobic drugs unlike o/w 
process. But, generally this method is used to encapsulate hydrophilic drugs such as 
peptides, proteins and vaccines. 
The concentration of the polymer is important where higher concentrations cause 
rapid phase separation and non-uniform microspheres. Agglomeration is a common 
problem in these systems due to the absence of emulsion stabilizer. The coacervate 
droplets adhere each other before complete phase separation. Adjustment of stirring 
rate, temperature and addition of an additive is enough to overcome this problem 
[106]. 
Requirements of solvents are easier in phase separation technique compared to 
solvent evaporation methods.  The nonsolvents affect the hardening and phase 
separation stages. The polymer and the drug should be non-soluble and also miscible 
in nonsolvent. The second nonsolvents should be easy to remove. Silicone oil, 
vegetable oils, low molecular weight polybutadienes can be used as first nonsolvents 
in phase separation method [106]. Aliphatic hydrocarbons such as hexane, heptane 
and petroleum ether can be used as second nonsolvents.  [106]. 
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2.4.1.4 Spray dry method 
The spray dry technique has been widely employed for the fabrication of micro 
particle systems. Injectible microspheres made of biodegradable polymers can be 
synthesized by the spray dry method. This method can be applied to heat resistant, 
heat sensitive, water-soluble and water insoluble drugs, as well as to hydrophobic 
and hydrophilic polymers [106]. The phase separation method has difficulties such as 
mass production, requiring large quantities of organic solvents, removal of residual 
solvents. Also, double emulsion method requires many steps with low entrapment 
efficiencies and high burst releases. In contrast, spray drying method is rapid and 
convenient. The technique can be adapted to industrial scale procedures. The 
solubility of the drug and the polymer is less dependable in this method. The method 
is done by spraying polymer containing solution through heated chamber which lead 
polymer precipitation [107].  
There only may be a loss of product during spray-drying caused by the adhesion of 
the microspheres to the spray drier apparatus. A double-nozzle spray drying 
technique is developed to overcome this problem which includes mannitol as an anti-
adherent. 
2.4.2 Controlled release applications 
Acceleration on the formulation of drug delivery devices has increased rapidly, since 
injectable microspheres are used in treatments. Injectable microspheres are 
administrated when insertion of large implants avoided. Microspheres larger than 
6µm are not used due to acute toxicity reaction associated with capillary blockage in 
pulmonary circulation.  Microspheres are used in delivery of peptides, vaccines and 
variety of drugs. Especially, targeted drug delivery is the focus point of the studies. 
Targeted delivery of drugs can be summed up in three subjects such as oral and brain 
delivery and cancer therapy.  
An example of oral delivery of polymeric carriers is the uptake of microspheres by 
the Peyers Patches in gut associated lymphoid tissue. Peyer Patches are determined 
by M cells that overlay the lymphoid tissue.  The aim is to bind the polymeric 
carriers to the apical membrane of the M cells. There have been only two published 
phase I clinical trials on oral uptake of polymeric carriers. Another application of 
microspheres is the mucosal delivery of cancer vaccines. For this system, 
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microspheres are designed to increase the uptake of antigens by the M cells to 
enhance the mucosal immune response and to induce long and slow antigen release. 
This approach is validated by showing oral immunization of mice with 
phosphorylcholine. The aim of cancer vaccines are not only target and kill tumor 
cells in a specific manner, but also to alert immune system, so the residual tumor 
kept in check. 
Brain delivery of microspheres is a challenging issue because of restricting effect of 
the blood brain barrier. The most achieved work in this area is delivering drugs via 
receptor-mediated transcytosis without damaging blood brain barrier by pegylated 
immunoliposomes [108]. Copolymers of PEG with different functionalities had been 
synthesized for this purpose [109].  Administration of the polymeric carriers which 
are not able access through blood brain barrier should be done by surgery.  
The most targeting application of polymeric carriers is against cancerous cells and 
tumor targeting with incorporation of chemotherapeutic agents. Tumors can be 
exploited by the polymeric carriers via overexperssion of specific antigens on cancer 
cells.  
2.5 Applications of copolymers of biodegradable polymers 
Biodegradable aliphatic polyesters have an extensive family of polymers which some 
of them are commercially available and have been widely studied for biomedical 
purposes. Copolymers of these biodegradable polyesters have the potential to tune up 
the properties for specific medical requirements. In this view of significance, some 
examples of copolymers of aliphatic polyesters on biological applications are given 
below.  
Triblock copolymers of PLGA and PEG show thermoreversible characteristics. ABA 
and BAB type of copolymers where A and B represents PEG and PLGA 
respectively, are good candidates for slowly dissolving implants and drug delivery 
systems [110, 111]. Jeong and coworkers has extensively studied on synthesis, 
characterization and use of PEG-PLGA-PEG copolymers as drug delivery systems 
[112,113]. If the polymer presents as a solution with a concentration below critical 
gel concentration, the solution would exist as a sol. But if the solution is heated 
above the critical gel concentration then the solution undergoes a phase transition to 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
33 
a non-flowing gel [112, 113].  This property gives the opportunity for injection of the 
material as a liquid. The polymer turns into a semi-solid gel upon heating in the 
body. This phase transition property of brings convenience for many applications. 
BAB type copolymer is commercialized under trade name ReGel and has been used 
for the release of insulin, porcine growth hormone, recombinant hepatisis B surface 
antigen and granulocyte colony stimulating factor [111, 114, and 115]. Nowadays, 
formulation of ReGel with paclitaxel under trade name OncoGel is under 
investigation for treatment of breast [111], pancreatic[116] and primary brain cancers 
[116]. 
Copolymers of polyanhdyrides can given as an another example of a biodegrdable 
polymers. Derivatives of polyanhydrides have also been used for delivery of proteins 
and peptides [117]. According to a study of Hanes group, poly(anhyride-co-imides) 
degrades by erosion which gives an opportunity to control release of drugs [118]. 
Poly(ε-caprolactone-co-glycolic acid) is a good example of biodegradable 
copolymers. The copolymer has variety of usage areas such as sutures, dermal tissue 
repair and controlled release applications. It is repeorted that, sutures coated with 
poly(ε-caprolactone-co-glycolic acid) copolymer is less stiff than sutures coated with 
other materials [119]. The copolymer has used as a wound-healing matrix in chronic 
wounds for dermal tissue repair [120]. Mostly synthetic and animal derived materials 
are used in this manner. A similar approach is developed by Yannas and Burke 
[121]. They used completely synthetic material instead of animal derived materials 
[121]. Poly(ε-caprolactone-co-glycolic acid) copolymer is still need to be improved 
for long term uses. 
Bio-stable polyurethanes have been widely investigated as drug delivery devices. 
Having excellent biocompability in the body brought the need for biodegradable 
polyurethanes with it [122]. Biodegradable polyurethanes are good candidates for 
bone regenerative medicines. PLA, PGA and PCL are widely used as soft segments 
of polyurethanes [123]. Additionally, biodegradable polyurethanes are investigated 
as drug carrier system after administration of PLA, PGA or PCL segments [124].  
In conclusion, copolymerization of common biodegradable polymers is a necessity. 
Improving the properties of the biodegradable polymers by copolymerization gives a 
great advantage on medical applications. Adjustment of controlled release of drugs, 
degradation profiles, biocompability, and strength of the tissues are just a few 
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examples of the benefits provided by copolymerized biopolymers. But still, having 
superior properties by copolymerization is needed to be improved for better results. 
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3. EXPERlMENTAL PART 
3.1 Materials and Chemicals 
3.1.1 Monomers 
Styrene (S, 99%, Aldrich):  
It was passed through a basic alumina column to remove the inhibitor before use.  
4-vinyl benzyl chloride (CMS,  90%, Acros): 
It was passed through a basic alumina column to remove the inhibitor before use.  
L(-)-Lactide(LA, Polysciences):  
It was crystallized from dry benzene. 
Glycolide (GA, 99,9 %, Polysciences):  
It was crystallized from dry benzene. 
ε- Caprolactone (CL, %97 Aldrich ): 
It was distillated under vacumm to remove the inhibitor before use. 
3.1.2 Polymers 
Poly(DL-lactic-co-glycolic acid) (PLGA, 50:50, inherent viscosity (0.55-0.75), 
Lactel): 
It was used as received. 
Poly(DL-lactic-co-glycolic acid) (PLGA, 50:50, inherent viscosity (0.75-0.96), 
Lactel): 
It was used as received. 
Poly(DL-lactic-co-glycolic acid) (PLGA, 50:50, inherent viscosity (0.96-1.20), 
Lactel): 
It was used as received. 
Poly(DL-lactic-co-glycolic acid) (PLGA, 75:25, inherent viscosity (0.55-0.75), 
Lactel): 
It was used as received. 
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Poly(DL-lactic-co-glycolic acid) (PLGA, 85:15, inherent viscosity (0.55-0.75), 
Lactel): 
It was used as received. 
Poly(vinyl alcohol) (PVA, 88% hydrolized, Mw: 25000g/mol, Polysciences): 
It was used as received. 
Poly(ethylene glycol) (PEG, Mw:2000, Polysciences): 
It was used as received. 
Poly(ethylene glycol) (PEG, Mw:750, Sigma-Aldrich ): 
It was used as received. 
3.1.3 Solvents 
Dichloromethane (J.T. Baker):  
It was dried with calcium chloride and distilled over P2O5. It was stored over 
molecular sieves for use as a solvent in the photopolymerization experiments.  
Methanol (Technical):  
It was used for the precipitation of polymers without further purification.  
Tetrahydrofuran (THF, 99.8%, J.T.Baker):  
(a) It was used as eluent for chromatography as received (High Performance Liquid 
Chromatography Grade).  
(b) For use in the chemical reactions, it was dried and distilled over 
benzophenone/sodium.  
N,N-Dimethyl formamide (DMF, 99%, J. T. Baker): 
It was used as recieved. 
3.1.4 Other chemicals 
Dicyclohexylcarbodiimide (DCC, Sigma-Aldrich): 
It was used as recieved. 
 4-(N,N’-dimethyl)amino pyridine (DMAP, Sigma-Aldrich): 
It was used as recieved. 
Sodium azide (NaN3, 99% , Aldrich): 
It was used without further purification.  
Copper(I) bromide (CuBr, 98%, Acros):  
It was used as recieved. 
Propargyl alcohol (C3H4O, 99%, Aldrich):  
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It was used without further purification.  
2,2-dipyridyl (99%, Acros Organics): 
It was used as recieved. 
Imatinib Mesylate 
 It was kindly provided by Novartis. 
Na2HPO4  (99.95%, Sigma Aldrich): 
It was used as recieved. 
KH2PO4  (99%, Merck): 
It was used as recieved. 
KCl (99.99%, Sigma Aldrich): 
It was used as recieved.  
NaCl (99%, Merck): 
It was used as recieved.  
Tin octoate ( Sn(Oct)2, Sigma Corp.): 
It was used as recieved. 
3.2 Equipments 
3.2.1 Nuclear magnetic resonance spectroscopy (NMR)  
(a) 1H NMR measurements were recorded in CDCl3 with Si(CH3)4 as internal 
standard, using a Bruker AC250 (250.133 MHz) instrument.  
(b) 1H NMR and 13C NMR measurements were recorded in CDCl3 with Si (CH3)4 as 
internal standard, using Bruker Spectrospin Avance DPX-400 (400 MHz) 
spectrometer.  
3.2.2 Infrared spectrophotometer (FT-IR)  
FT-IR spectra were recorded on a Perkin Elmer FTIR Spectrum One B spectrometer.  
3.2.3 Gel permeation chromatography (GPC)  
(a) Gel permeation chromatography (GPC) analyses were performed with a set up 
consisting of a Waters 410 Differential Refractometer, a Waters 515 HPLC Pump 
and an apparatus equipped with three Waters ultrastyragel columns (HR series 4, 3, 2 
narrow bore), with THF as the eluent at a flow rate 0.3 mL/min. Molecular weights 
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were calculated on the basis of a calibration curve recorded with mono disperse 
polystyrene standards.  
(b) Gel permeation chromatography (GPC) measurements were obtained from a 
Viscotek GPCmax Autosampler system consisting of a pump, a Viscotek UV 
detector and Viscotek a differential refractive index (RI) detector. Three ViscoGEL 
GPC columns (G2000HHR, G3000HHR and G4000HHR), (7.8 mm internal 
diameter, 300 mm length) were used in series. The effective molecular weight ranges 
were 456–42800, 1050–107000, and 10200–2890000, respectively. THF was used as 
an eluent at flow rate of 1.0 mL min-1 at 30°C. Both detectors were calibrated with 
PS standards having narrow molecular weight distribution. Data were analyzed using 
Viscotek OmniSEC Omni-01 software. Molecular weights were calculated with the 
aid of polystyrene standards.  
(c) The GPC set-up (TD-GPC) with an Agilent 1200 model isocratic pump, four 
Waters Styragel columns (guard, HR 5E, HR 4, HR 3, and HR 2), and a Viscotek 
TDA 302 triple detector (RI, dual laser light scattering (LS) (λ = 670 nm, 90° and 7°) 
and a differential pressure viscometer was conducted to measure the absolute 
molecular weights in THF with a flow rate of 0.5 mL/min at 35 °C. All three 
detectors were calibrated with a PS standard having narrow molecular weight 
distribution (Mn = 115,000 g/mol, Mw/Mn = 1.02, [ƞ] = 0.519 dL/g at 35 °C in THF, 
dn/dc = 0.185 mL/g) provided by Viscotek company. Data were collected by using 
Omni-Sec version 4.5 software from Viscotek Company. 
3.2.6 High pressure liquid chromatography (HPLC) 
HPLC assays were performed on a a Nucleosil 100-5- C18 AB (Macherey-Nagel, 
Duren, Germany) column equipped with a guard column (8 mm x 4mm i.d.) filled 
with the same packing material. The imatinib mesylate concentration in aqueous 
phase was determined using HPLC (Shimadzu LC-10Ai, Japan). Imatinib mesylate 
was isolated isocratically at flow rate of 0.8 mL/min using mobile phase consisting 
of methanol:water (70:30) with UV detection at 261 nm. 
3.2.5 Scanning electron microscopy (SEM)  
The surface morphology of the microspheres was determined by scanning electron 
microscopy (JEOL JSM-633 5F, Oxford Instruments). Microspheres were mounted 
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on metal stubs with conductive silver paint and then sputtered with a 150-Å-thick 
layer of gold for SEM analysis. 
3.2.6 Particle size analyzer 
Mean particle sizes were determined using a Mastersizer X (Malvern Inst.). 
3.2.7 Shaker 
Innova 4230 ıncubator used as a shaker bath (37˚C) at 200 rpm. 
3.2.8 Homogenizer 
Laboratory Mixer-L4R (Silverson) used as homogenizer. 
3.3 Preparation Methods 
3.3.1 Preparation of imatinib mesylate loaded microspheres from various 
poly(lactic-co-glycolic acid) (PLGA) copolymers 
Controlled release behavior of microspheres made of PLGA with different  LA:GA  
ratios and molecular weights are studied. Microspheres were prepared by double 
emulsion solvent evaporation method (W/O/W). Briefly 0.5g of polymer was 
dissolved in 3 mL methylene chloride (DCM). 250 µl of aqueous drug solution was 
emulsified into the organic phase by vortex. This emulsion was added to 400mL 
aqueous phase containing 1% (w/v) PVA by drop wise and stirred at 1000 rpm for 5 
min. The resulting solution was kept stirring at 500 rpm for 3 hours to allow solvent 
evaporation and hardening microspheres. The microspheres were then filtered and 
dried under vacuum. Final products were stored at -20 ºC. 
3.3.1.2 Calculating the encapsulation efficiency of imatinib mesylate loaded 
PLGA microspheres 
Encapsulated amount of drug was measured by suspending 10 mg PLGA 
microspheres in 1.5 mL dichloromethane. The samples were placed in a shaker 
maintained at 200 rpm for 2 hours. Then 2 mL of PBS buffer pH 7.4 is added and the 
samples placed back in the shaker for another 2 hours. The samples were taken out of 
shaker and centrifuged at 10.000 rpm for 5 minutes and 0.6 mL of supertant was 
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taken for analysis. The drug concentration in aqueous phase was determined by 
HPLC at 261 nm. 
Actual drug loading and drug encapsulation efficiency (EE) were calculated using 
the following equations: 
Theoretical drug loading = drug (tot.)/ (drug (tot.) +polymer) 
Actual drug loading = drug (enc.) / (drug (tot.)+polymer) 
Encapsulation Efficiency = actual drug loading/ theoretical drug loading x 100%. 
3.3.1.3 In vitro release studies of imatinib mesylate loaded PLGA microspheres 
In vitro release of imatinib mesylate from microspheres was measured by suspending 
10 mg microspheres in 1 mL PBS buffer pH 7.4. The samples were placed in a 
shaker maintained at 37˚C and shaken at 200 rpm. At predetermined time intervals 
the samples were taken out of shaker and centrifuged at 10.000 rpm for 5 minutes 
and 0.6 mL of supernatant was taken for analysis and fresh medium of equal volume 
was added in the meantime. The precipitated microspheres was resuspended in the 
medium and placed back in the shaker. The imatinib mesylate concentration in 
aqueous phase was determined by HPLC at 261 nm. 
3.3.2 Synthesis of polystyrene-g-poly (lactic acid) (PS-g-PLLA) and polystyrene-
g-poly (lactic-co-glycolic acid) (PS-g-PLLGA)  
PS-g-PLLA and PS-g-PLLGA are synthesized through combination of Nitroxide 
Mediated Free Radical Polymerization (NMRP) and Ring Opening Polymerization 
(ROP) with copper (I)-catalyzed “Click” chemistry.  First, the click component, 
azido-functional PS (PS-N3) was prepared by copolymerization of styrene and 
chloromethyl styrene by NMRP followed by the conversion of chlorine groups of the 
resulting copolymer to azido groups by using NaN3 in N, N-dimethylformamide. 
Propargyl functional APEs were prepared independently by ROP of lactic acid and 
glycolic acid using tin octoate in the presence of propargyl alcohol at 125 ˚C. Finally, 
PS-N3 was coupled with the resulting polymers by click chemistry to yield graft 
copolymers (PS-g-PLLA and PS-g-PLLGA, respectively). 
3.3.2.1 Synthesis of poly(styrene-co-chloromethylstyrene), P(S-co-CMS) and 
polystyrene-azide PS-N3  
Poly(styrene-co-chloromethylstyrene), P(S-co-CMS), prepared via nitroxide-
mediated radical polymerization (NMRP) of styrene (S) and chloromethylstyrene 
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(CMS) at 125 ˚C for 18 h. The obtained polymer precipitated from methanol and 
dried under vacuum.  Chlorine units of the P(S-co-CMS) polymer successfully 
converted to azide groups. P(S-co-CMS) (1.00 g, 1.24 x 10-4 mol) dissolved in DMF 
and reacted with NaN3 (8.85 x 10
-3 g, 1.36 x 10-4 mol) 1.1 times excess in mol of Cl 
units of P(S-co-CMS) polymer at room temperature for 24 h. The resulting polymer 
was filtered and precipitated from methanol and finally dried under vacuum. The 
synthesis of P(S-co-CMS) and PS-N3 is shown in Figure 3.1. 
1H-NMR (CDCl3) δ (TMS, ppm) for P(S-co-CMS) : 7.04 -6.54 (aromatic protons), 
4.5 (CH2-Cl), 1.82-1.42 (aliphatic protons)  
1H-NMR (CDCl3) δ (TMS, ppm) for PS-N3: 7.04 -6.54 (aromatic protons), 4.25 
(CH2-N3), 1.82-1.42 (aliphatic protons)  
 
 
Figure 3. 1: Synthesis of P(S-co-CMS) and PS-N3. 
3.3.2.2 Synthesis of acetylene terminated PLLA and PLLGA  
Acetylene terminated PLLA synthesis is conducted by ring opening polymerization 
of monomer. L-lactide (2.00g, 13.80 mmol) and propargyl alcohol (15.50 mg, 0.27 
mmol) reacted in the presence of Sn(Oct)2 (catalytic amount) at 125˚C under N2 for 
24 hours. The resulting polymer was diluted by dichloromethane and precipitated 
from cold methanol and finally dried under vacuum. The synthesis of acetylene 
terminated PLLA and PLLGA are shown in Figure 3.2. 
1H-NMR (CDCl3) δ (TMS, ppm): 5.16-5.13 (CH-CH3), 4.32 (CH2-O), 2.50 (C≡CH),   
1.58 (CH-CH3). 
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Figure 3. 2: Synthesis of acetylene terminated PLLA and PLLGA. 
The same procedure using L-lactide and glycolide with 3:1 mole ratios, respectively 
is followed for the synthesis of corresponding PLLGA.  
1H-NMR (CDCl3)δ (TMS, ppm): 5.16-5.13 (CH-CH3), 4.81 (CH2-C=O), 4.32 (CH2-
O),  2.50 (C≡CH), 1.58 (CH-CH3). 
3.3.2.3 Click reaction of PS-N3 and PLLA and/or PLLGA 
To a roud bottom flask equipped with a magnetic stirring bar, PS-N3 (1.00 g, 1.96 
mmol), PLLA (1.94 g, 0.12 mmol),  ligand (2, 2-dipyridyl, 0.24 mmol), catalyst 
(CuBr, 0.12 mmol) were dissolved in 7 mL of dry THF and stirred at room 
temperature under N2.  After the reaction, the mixture was diluted with THF and then 
passed through a column of neutral alumina to remove metal salt. The reaction 
mixture was concentrated and precipitated from cold methanol. The final product 
was washed with methanol and dried for 24 h in a vacuum oven at room temperature. 
The synthesis of PS-g-PLLA and PS-g-PLLGA are shown in Figure 3.3. 
1H-NMR (CDCl3) δ (TMS, ppm): 7.04 -6.54 (aromatic protons), 5.16-5.13 (CH-
CH3), 4.20 (CH2-triazole ring), 3.48 (CH2-O), 1.58 (CH-CH3). 
Same procedure is followed for the PLLGA. 
1H-NMR (CDCl3) δ (TMS, ppm): 7.04 -6.54 (aromatic protons), 5.16-5.13 (CH-
CH3), 4.81 (CH2-C=O), 4.20 (CH2-triazole ring), 3.48 (CH2-O), 1.58 (CH-CH3). 
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Figure 3. 3: Synthesis of PS-g-PLLA and PS-g-PLLGA. 
3.3.2.4 Degradation studies of PS-g-PLLA and PS-g-PLLGA 
The in vitro degradation studies of PS-g-PLLA and PS-g-PLLGA were performed at 
37˚C in phosphate buffer saline (PBS) (contains sodium chloride, sodium phosphate) 
at pH: 7.4. Graft copolymer films, prepared by solvent casting were placed in vials, 
each containing 15 mL PBS. The vials were incubated at 37˚C for various periods of  
time during 6 weeks. The buffer solution was replaced every 48 h. The films were 
subsequently dried at 25ºC in vacuum until a constant weight was reached. The % 
change in mass for each film was calculated as follows: 
% Change in mass =  mi -mf /mi  x 100 
Where mf is the final mass and mi is the inital mass.  
3.3.2.5 Preparation of imatinib mesylate loaded PS-g-PLLA and PS-g-PLLGA 
microspheres 
Controlled release behavior of microspheres made of PLGA with different 
compositions and molecular weights, PS-g-PLLA and PS-g-PLLGA are studied. 
Microspheres were prepared by solvent evaporation method (W/O/W). Briefly 0.5g 
of polymer was dissolved in 3 mL methylene chloride (DCM). 250 µl of aqueous 
drug solution was emulsified into the organic phase by vortex. This emulsion was 
added to 400mL aqueous phase containing 1% (w/v) PVA by drop wise and stirred at 
1000 rpm for 5 min. The resulting solution was kept stirring at 500 rpm for 3 hours 
to allow solvent evaporation and hardening microspheres. The microspheres were 
then filtered and dried under vacuum. Final products were stored at -20 ºC. 
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3.3.2.6 Calculating the encapsulation efficiency of imatnib mesylate loaded PS-
g-PLLA and PS-g-PLLGA microspheres 
Encapsulation efficiencies of imatnib mesylate loaded PS-g-PLLA and PS-g-PLLGA 
microspheres were calculated as in section 3.3.1.2. 
3.3.2.7 In vitro release studies imatinib mesylate loaded of PS-g-PLLA and PS-g-
PLLGA microspheres 
In vitro release of imatinib mesylate loaded PS-g-PLLA and PS-g-PLLGA 
microspheres were determined as in section 3.3.1.3. 
3.3.3 Synthesis of ABC type miktoarm star PS-PLA-PEG copolymer 
An ABC type miktoarm star copolymer possessing PS, PLA and PEG arms was 
synthesized by combining Atom Transfer Radical Polymerization (ATRP) and ROP 
with two click chemistries, namely thiol–ene and copper catalyzed azide–alkyne 
cycloaddition (CuAAC).  For this purpose, a core 1-(allyloxy)-3-azidopropan-2-ol 
with allyl and azide functionalities was synthesized in two steps. Then, clickcable 
polymers, polystyrene with thiol functionality (PS-SH) and poly(ethylene glycol) 
with alkyne functionality (PEG-acetylene) were independently prepared. As the first 
step of the grafting onto process, PS-SH was thiol–ene clicked onto the core to yield 
PS-N3-OH. The second arm was then incorporated on to the core by the Ring 
Opening Polymerization (ROP) of   l-(-)-Lactide (LA) using as PS-N3-OH initiator 
and tin(II) 2-ethylhexanoate as catalyst. Finally, alkyne-PEG-acetylene was bonded 
to the resulting PLA-PS-N3 using CuAAC click reaction. 
3.3.3.1 Synthesis of the core compound, 1-(allyloxy)-3-azidopropan-2-ol [125] 
Allyl glycidyl ether (5.0 mL, 1eq) was dissolved in 150 mL ethanol in a 500 mL 
round bottom flask equipped with a stirrer. Then, sodium azide (12 g, 3 eq) in 120 
mL water was simply added to the solution and the reaction mixture was left stirring 
for overnight. The solution was successively extracted with CH2Cl2 and the organic 
phase was dried with MgSO4, filtrated and evaporated under vacuum to give viscous 
yellow liquid (Yield: 96%). The synthesis of 1-(allyloxy)-3-azidopropan-2-ol is 
shown in Figure 3.4. 
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1H NMR (CDCl3, 250 MHz): δ = 5.83 (m, 1H, -CH=), 5.24 (m, 1H, trans CH2=), 
5.16 (m, 1H, cis CH2=) 3.94 (d, 2H, CH2=CH-CH2-O-), 3.40 (p, 1H, -CH-OH), 3.88 
(d, 2H, -O-CH2-), 3.30 (d, 2H, -CH2-N3) 3.13 (s, 1H, -OH); FT-IR (ATR): 3420, 
2883, 1703, 1584, 1438, 1395, 1256, 1175, 1082, 873, 762 cm-1. 
 
Figure 3. 4: Synthesis of the core compound, 1-(allyloxy)-3-azidopropan-2-ol. 
3.3.3.2 Synthesis of polystyrene with ω-xanthate functionality (PS-Xant) [126] 
Into a two necked flask equipped with a stirrer, PS-Br (0.9 g, 1eq), potassium 
xanthate (0.4 g, 5 eq) and 8 mL DMF was added under N2 atmosphere. The reaction 
mixture was stirred for 12 h at room temperature and precipitated in 10 fold excess of 
methanol to yield PS-Xant. (Mn,GPC = 2200 g/mol, Mw/Mn = 1.20) 
3.3.3.3 Synthesis of polystyrene with ω-thiol functionality (PS-SH) [125] 
Into a two necked flask equipped with a stirrer, DMF (8 mL), PS-Xant (0.7 g, 1eq) 
and metallic zinc (60 mg, 3 eq) were added under N2 atmosphere. Next, 1,2-
ethandithiol (0.3 mL, 10 eq) was added to the reaction media by a syringe. The 
reaction mixture was stirred for 3 h and precipitated into slightly acidic 10 fold 
excess methanol/water mixture (10:1, vol/vol) to give a white powder solid. (Yield: 
95%) Mn,NMR = 1980, Mn,GPC = 1950 g/mol, Mw/Mn= 1.18. The synthesis of 
polystyrene with ω-thiol functionality (PS-SH)is shown in Figure 3.5. 
 
Figure 3. 5: Synthesis of polystyrene with ω-thiol functionality (PS-SH). 
3.3.3.4 Synthesis of PS-core  
Into a two necked flask equipped with a stirrer, toluene (5 mL), the core (0.24 g, 5 
eq), BAPO (0.63 g, 5eq), and PS-SH (0.6 g, 1eq) were added in that order under N2 
atmosphere. The reaction flask was irradiated with visible light (400-500 nm) for 4 
hours and then precipitated into methanol. The obtained polymer was collected by 
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filtration and dried under vacuum. (Yield: 94%) Mn,NMR = 2270, Mn,GPC = 2250 g/mol, 
Mw/Mn= 1.18.  The synthesis of PS-core is shown in Figure 3.6. 
 
Figure 3. 6: Synthesis of PS-core. 
 
3.3.3.5 Synthesis of PS-PLA-N3 
Synthesis of PLA-PS-N3 is performed by the ring opening polymerization of L-
lactide monomer where polystyrene with –OH functionality emerging from the core 
was used as initiator.  l-(-)-Lactide (0.5 g, 34.5 mmol) and PS-core (0.3 g, 0.15 
mmol) reacted in the presence of Sn(Oct)2 (catalytic amount) at 125˚C under N2 for 
24 hours. The resulting polymer was diluted by CH2Cl2 and precipitated from cold 
methanol. Precipitated polymer dried under vacuum. Mn,NMR = 3480, Mn,GPC = 2860 
g/mol, Mw/Mn= 1.32. The synthesis of PS-PLA-N3 is shown in Figure 3.7. 
 
Figure 3. 7: Synthesis of PS-PLA-N3. 
3.3.3.6 Synthesis of PEG-acetylene 
Me-PEG (Mn = 2000 g/mol) (2 g, 1 mmol) was dissolved in 50 mL of CH2Cl2. 4-
Pentynoic acid (0.294 g, 3.00 mmol), DMAP (0.12 g, 1.0 mmol) and DCC (0.62 g, 
3.0 mmol) in 5 mL of dichloromethane were added to the solution in that order. The 
reaction mixture was stirred overnight at room temperature. It was filtered and 
evaporated, and the remaining product was purified by column chromatography over 
silica gel eluting first with CH2Cl2/ethylacetate (1:1), and then with methanol/ 
CH2Cl2 (1:10). Finally, the organic phase was evaporated to give PEG-acetylene. 
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3.3.3.7 Click reaction of PLA-PS-N3 with PEG-acetylene 
To a Schlenk tube equipped with a magnetic stirring bar, PLA-PS-N3 (0.24 g, 1 eq), 
PEG-acetylene (0.22 g, 1.5 eq), PMDETA (22 μL, 1.5 eq), and CuBr (15 mg, 1.5 eq) 
were added and dissolved in 3 mL of DMF. The tube was degassed by three freeze-
pump-thaw cycles, left under vacuum, and placed in a thermostatted oil bath at 60 
0C. After 24 h, the reaction mixture was diluted with THF and then passed through a 
column of neutral alumina to remove metal salts. The reaction mixture was 
concentrated and precipitated into methanol. The resulting polymer (PS-PLA-PEG) 
was dried in vacuum at room temperature. (Yield: 94%, Mn,NMR= 5940 g/mol, 
Mn,GPC= 3010 g/mol, Mw/Mn= 1.21) The synthesis of PS-PLA-PEG is shown in 
Figure 3.8. 
 
Figure 3. 8: Synthesis of PS-PLA-PEG. 
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4. RESULTS AND DISCUSSION 
The main objective of this thesis is to synthesize new biodegradable polymers for 
various biomedical applications. The first part consist of controlled drug delivery 
studies of microspheres made of PLGA copolymers with different properties. 
Afterwards new biodegradable polymers were synthesized. Hydrolytic degradation 
profiles were studied for the polymers which are intented to use in controlled release 
applications. Controlled release studies of proper polymers were also investigated. 
Novel synthesis of a new star polymer consists of poly(styrene), poly(lactic acid) and 
poly(ethylene glycol) was synthesized. Pyrolysis of the polymer was investigated for 
future applications. In the final work, a graft copolymer of poly(p-phenylene) (PP) 
and PEG segments was synthesized to take the advantage of fluorescence property 
gained by the conjugation of the polymer for biomedical applications. 
4.1 Controlled Release Studies of various PLGA copolymers 
Commercial PLGA copolymers are used for fabrication of microspheres to compare 
after synthesis of new biopolymers. Imatinib mesylate, used as a hydrophilic and an 
effective drug for the treatment of craniopharyngiomas which grow by 
vascularization. Chemical structure of imatinib mesylate is shown in Figure 4.1. 
Craniopharyngioma is a type of brain tumor derived from pituitary gland embryonic 
tissue, that occurs most commonly in children but also in men and women in their 
50s and 60s. We aimed to synthesize and characterize different imatinib mesylate 
containing PLGA microspheres by modifying certain parameters to optimize the 
drug release characteristics. Microspheres were prepared by double emulsion/ 
solvent evaporation method. Nearly, eighty different microspheres were synthesized 
and optimized microspheres were chosen for investigation. Influence of process 
parameters on microsphere encapsulation, initial burst release and release profile 
from PLGA microspheres were studied. Properties of the microspheres are listed in 
the Table 4.1. 
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Figure 4. 1: Chemical structure of imatinib mesylate. 
Table 4. 1: Characteristics of imatinib mesylate loaded PLGA microsphere prepared      
at different conditions 
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4.1.1 Influence of polymer nature 
The influence of PLGA polymers with the different lactic acid/glycolic acid ratios 
(50/50, 75/25, 85/15) with the same molecular weight on drug release is investigated.  
As it can be seen from the Table 4.1, EE % decreased for the microspheres prepared 
from 50/50 to 85/15. This behavior can be explained by the lactic acid ratio. Due to 
the hydrophobic behavior of lactic acid units encapsulation of drug which is 
hydrophilic decreases. Also drug bursts of these microspheres relatively decreases as 
the lactic acid ratio increases.   
In vitro release of imatinib mesylate from different microspheres is shown in Fig.4.1. 
It has been reported that the water uptake and degradation rate is higher for 
hydrophilic polymers [127].  
 
Figure 4. 2 : Influence of LA:GA ratio on the release of imatinib mesylate from 
PLGA  microspheres. 
It is expected that the release from the polymer with the ratio 50/50 would be the 
faster than other two.  The slower release of the drug should  belong to the 
microspheres  made from the polymer with the ratio of 85/15 but experiments 
showed that difference between 75/25 and 85/15 is not significant as we expected. 
Figure 4.3 shows the surface morphology of microspheres prepared from PLGA 
polymers with the different lactic acid/glycolic acid ratios. 
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Figure 4. 3 : Surface morphology of microspheres prepared from PLGA polymers 
with the different lactic acid/glycolic acid ratios 50/50 (a), 75/25 (b) 
and 85/15 (c). 
4.1.2 Influence of internal aqueous phase (W1) volume /continuous phase (W2) 
volume 
Keeping the other conditions constant, effect of internal phase volume on properties 
of microspheres was investigated (Table 4.1).  The EE and drug loading nearly did 
not change when W1 volume increased from 125 to 250 µL. The initial drug bursts 
were 17.5 and 18.76% at W1 volume 125 and 250 µL, respectively. Low volumes of 
W1 phase resulted in a minimal micro porosity of the polymer matrix, whereas high 
W1 volumes caused an increasing number of micropores and channels thereby 
facilitating the rapid initial diffusion of encapsulated drug [128]. On the other hand 
small internal phase is surrounded by a thicker organic phase and the diffusion rate 
of imatinib mesylate into the continuous phase decreased in the solvent evaporation 
step.  
 
Figure 4. 4 : Influence of internal phase volume on the release of imatinib mesylate 
from  PLGA microspheres. 
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The effect of internal phase volume on the in vitro release rate of imatinib mesylate 
is shown in Fig.4.4.  The release rate of the drug increases as the W1 volume 
increases from 125 to 250µL. This is in an agreement with the previous results about 
encapsulation efficiency which is related with the high W1 volumes can cause 
microporisty.  And the release rate increases with increasing W1 volume. 
 
Figure 4. 5 : Surface morphology of microspheres prepared at different continuous 
phase volume 100mL (a), 200 mL (b), 400 mL (c). 
Influence of the continuous phase volume (W2) on properties of microspheres also 
studied (Table 4.1).  As it can be seen from the table EE slightly increased with the 
increasing W2. In addition to that there is a remarkable change in initial burst 
release.  This can probably explained by the fact that the solubility of DCM in water 
is about 2% (v/v) and due to some loss of DCM in the first emulsion step, 100mL 
W2 volume might be sufficient for DCM to distribute into aqueous phase 
immediately. Further increase in W2 will adversely cause drug loss or drug 
redistribution on the microsphere surface in the hardening stage due to the increased 
concentration gradient. This explanation is in good agreement with initial drug burst 
data [129]. 
 
Figure 4. 6 : Influence of external phase volume on the release of imatinib mesylate 
from PLGA microspheres. 
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The effect of external phase volume on in vitro release of imatinib mesylate is shown 
in Fig. 4.6. Microspheres with the W2 200 and 100 mL nearly followed the same 
path with each other. But the microsphere with the W2 volume 400 mL has higher 
release rate. This can be explained by the same reasons with initial burst releases and 
also different drug distributions in microspheres could cause higher initial drug 
bursts when the hydrophilic drug substance is mainly located close to the surface of 
the microspheres [130]. 
4.1.3 Influence of polyvinyl alcohol concentration in the external phase 
PVA concentrations in the external phase are main factors on influencing the surface 
and the particle size of microspheres. The effect of PVA concentrations in external 
water phase on microspheres is examined (Table 4.1). It is known that PVA 
concentration is an important factor on the particle size of microspheres. The EE and 
drug loading decreased when PVA concentration increased from 0, 1 to 1%. It is 
known that increase in the PVA concentration leads to decrease in the size of 
microspheres which causes faster release of the drug. Influence of polyvinyl alcohol 
concentration in the external water phase on the   release of imatinib mesylate from 
PLGA microspheres is shown in Fig.4.7.   
 
 
Figure 4. 7: Influence of polyvinyl alcohol concentration in the external water 
phase on the   release of imatinib mesylate from PLGA microspheres. 
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Based on our experimental data the initial drug bursts were 5.63, 14.5 and 30.28 % at 
PVA concentrations 0.1, 0.5 and 1% respectively. Release profile of microspheres 
which made from external phase containing %1 of PVA compatible with the 
literature. In contrast the other two microspheres showed different release profiles. 
Surface morphology of microspheres prepared at different PVA concentrations is 
shown in Figure 4.8. As it can be seen from the surface structure of the microspheres 
low concentrations of PVA causes higher internal porosity and also external porosity. 
However, drug distribution of the microspheres at higher concentration of PVA is 
more uniform due to the dominant stabilization effect at high concentrations. 
 
Figure 4. 8: Surface morphology of microspheres prepared at different PVA 
concentrations 0.1 % (a), 0.5% (b) and 1% (c). 
4.1.4 Influence of polymer concentration   
EE and actual drug loading decreased while the concentration of polymer increasing 
as shown in Table 4.1. It can be agreed upon increasing viscosity of organic phase. 
Also initial burst decreased as concentration of polymer increasing due to surface 
morphology of microspheres (Figure 4.9). Because it is reported that, increasing 
viscosity of organic phase causes less external pores which results in low initial burst 
[131]. Also the high viscosity might restrict the diffusion of the drug in the matrix 
and compromise the contribution of external channels.  
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Figure 4. 9 : Influence of polymer concentration on the release of imatinib mesylate 
from PLGA microspheres. 
Release studies are in agreement with the literature that as the concentration of the 
organic phase increases the release of drug decreases [132]. On the other hand 
surface area/volume ratio with increasing size could be another cause for the 
decrease in release. 
As it can seen from Figure 4.10, size of microspheres increases with the increasing 
polymer concentration. This may be explained as it is more difficult for polymer 
solution to be broken into smaller oil droplets during the second emulsion.  
 
Figure 4. 10 : Surface morphology of microspheres prepared from different PLGA 
concentrations at 10% (a), 16.6% (b) and 25% (c). 
Also, water droplets trapped at interior of microspheres that evaporates and leave 
empty spaces after drying. The situation is can clearly be seen from the SEM photo 
of the microsphere prepared at 25% polymer concentration (Figure 4.10 (c)). 
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4.1.5 Influence of homogenization speed 
Keeping the other conditions constant, effect of homogenization speed on properties 
of microspheres was investigated (Table 4.1).The size of the microspheres is affected 
by viscosity of the polymer, internal water phase, homogenization speed, PVA 
concentration at external phase and molecular weight of the polymer. But the major 
factor beside these is the homogenization speed because it provides the energy to 
disperse the oil phase in water. According to our experimental data, EE decreases 
with the increasing stirring speed while release of imatinib mesylate increases 
(Figure 4.11). This may be explained by the decrease in the size of microspheres. 
Our previous studies indicate that, decrease in the size of microspheres result in rapid 
imatinib mesylate release. 
 
Figure 4. 11: Influence of homogenization speed on the release of imatinib mesylate 
from PLGA microspheres. 
Also our results are in agreement with the literature that high stirring speed causes 
smaller microspheres as it is shown in Figure 4.12. 
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Figure 4. 12: Surface morphology of microspheres prepared at different 
homogenization speeds, (a) 2000rpm, (b) 1000 rpm.                                                                                                                                         
4.1.6 Influence of theoretical drug loading 
Keeping the other conditions constant, properties of microspheres prepared with 
different theoretical drug loading are described in Table 4.1. According to our 
experimental data EE and actual drug loading did not change at theoretical drug 
loading 10 and 20%. However, EE decreased at increased theoretical drug loading 
40%.The initial drug loading decreased with the increasing theoretical drug loading. 
Since it is assumed that burst release is normally caused by the drug near the surface 
of microspheres, this implies that most of the drug substance was distributed in the 
internal matrix of the polymer instead of the surface. 
 
Figure 4. 13 : Influence of theoretical drug loading on the release of imatinib 
mesylate from PLGA microspheres. 
Influence of theoretical drug loading on the release of imatinib mesylate from PLGA 
microspheres showed in Fig. 4.13. Remarkable change is seen in the release profile 
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of microspheres which prepared with theoretical drug loading 20% in early stages of 
release but other two microspheres did not influenced by drug loading. 
4.1.7 Influence of Mw of PLGA polymers 
Influence of Mw of PLGA polymers on properties of microspheres shown in Table 
4.1. EE and actual drug loading increased with Mw of PLGA polymers significantly 
due to the increasing viscosity of the organic phase, which prevented out-flow of 
drug during hardening phase. 
 
 
Figure 4. 14: Influence of Mw of PLGA polymer on the release of imatinib mesylate 
from PLGA microspheres. 
Influence of Mw of PLGA polymer on the release of imatinib mesylate from 
microspheres is shown in Figure 4.14 and the results are compatible with the 
literature. As the Mw of the polymers increases, the release of the drug decreases due 
to the decreasing hydrolytic degradation of PLGA polymers. Viscosity of the oil 
phase increases with the higher Mw of the polymers that similar effects are seen with 
comparison at polymer concentration. Influence of Mw of PLGA polymer on surface 
morphologies of microspheres is shown in Figure 4.15.  
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Figure 4. 15 : Surface morphology of microspheres prepared from PLGA polymers 
inherent viscosities  at 0.55-0.75 (dL/g) (a), 0.75-0.95 (dL/g) (b) and 
0.95-1.2 (dL/g)  (c). 
Empty spaces caused by the evaporation of entrapped water as a result of higher 
concentration of the oil phase are again seen due to the increasing viscosity with the 
increasing molecular weight. Also, size of the microspheres increased with the 
increasing molecular weight of the polymer due to the thicker inner shell. 
4.1.8 Influence of PEG content in organic phase 
PEG (Mw:2000g/mol)  polymer is blended with PLGA to see the effect of increased 
hydrophilicity in oil phase. The influence of PEG content in organic phase is shown 
in Table 1. EE and actual drug loading decreased with the increasing content of PEG 
in organic phase due to hydrophilic behavior of PEG. Also, initial drug burst 
increased as PEG content increases. Hydrophilic nature and degradation rate of PEG 
results in fast release of drug. The release profiles of PEG containing microspheres 
are shown in Fig.4.16. The influence of PEG on surface of microspheres is shown in 
Figure 4.17. The results indicate that increased hydrophilicity of the polymer matrix 
causes porosity on the external surface of the microspheres. 
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Figure 4. 16: Influence of PEG content in organic phase on the release of imatinib 
mesylate from PLGA microspheres. 
 
Figure 4. 17: Surface morphology of microspheres prepared with PEG in organic 
phase 25% (a) and 50% (b). 
4.1.9 Influence of polymer blends  
Influence of PLGA blends with ratios LA:GA of 50:50 and 75:25 on the release of 
imatinib mesylate from microspheres is investigated. The influence of PLGA blends 
on actual drug loading, encapsulation efficiency and burst release is shown in Table 
4.2.  
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Table 4. 2: Influence of LA:GA ratio on PLGA blends. 
PLGA Blends 
 
Actual Drug 
Loading 
(%) 
 
EE 
(%) 
Burst 
Release 
(%) 
50:50 (2) /75:25 (1) 0,27 27,41 50,9 
50:50 (1) /75:25 (2) 0,22 22,96 14,35 
50:50 (1) /75:25 (1) 0,35 35,96 42,90 
50:50 (1) /75:25 (3) 1,3 103,65 47,84 
50:50 (3) /75:25 (1) 0,83 83,74 55,62 
50:50 (4) /75:25 (1) 0,6 60,25 88,615 
50:50 (1) /75:25 (4) 0,64 64,8 78,605 
 
The influence of PLGA polymer in organic phase with LA ratio of 75% on imatinib 
mesylate release is shown in Figure 4.18. 
 
Figure 4. 18: The influence of PLGA polymer in organic phase with LA ratio of  
            75% on imatinib mesylate release. 
As it can be seen from the Figure 4.18, when it is compared with previous 
microspheres, blending the PLGA polymer bearing LA ratio 50% with the polymer 
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bearing LA ratio 75% cause a decrease in release rates due to slower degradation rate 
of the PLGA polymer with LA ratio 75%.  
 
Figure 4. 19: Influence of mole ratios of PLGA polymers with different LA:GA     
           content on imatinib mesylate release. 
Increment in mole of PLGA polymer with LA ratio of 75% increases the 
encapsulation efficiency and decreases the release rate of drug release as shown in 
Table 4.2. This situation can be explained by the hydrophilic nature of LA content in 
the polymer composition. Influence of increment in mole of PLGA polymer with LA 
ratio of 75 % on cumulative release of drug is shown in Figure 4.19 An increase of 
PLGA polymer with LA ratio 50% in blend causes faster release. Influence of 
increased mole ratio of PLGA (LA:GA, 50:50) polymer is shown in Figure 4.19. 
Also, increase of PLGA polymer with LA ratio 50% causes a decrease in 
encapsulation efficiency where burst release of microspheres increased.  
The mole ratio of the PLGA with 50% LA content increased 3 fold of PLGA with 
LA content 75%. The influence of change in the mole ratio is shown in Figure 4.20. 
As it is expected an increase in the mole ratio of PLGA polymer with 50% of LA 
content result in higher release profile.  
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Figure 4. 20: Influence of mole ratios of PLGA polymers with different LA:GA     
           content on imatinib mesylate release. 
PLGA of 50% LA content with mole ratio 4 fold of PLGA with 75% followed 
similar release profile with  Figure 4.20 as it shown in Figure 4.21. Encapsulation 
efficiencies of microspheres prepared from blends containing higher mole ratio of 
PLGA with LA content 75% is increased according to higher LA content in organic 
phase. 
 
 
Figure 4. 21: Influence of mole ratios of PLGA polymers with different LA:GA     
         content on imatinib mesylate release. 
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As a result of this work, 80 PLGA microspheres with different characteristics were 
synthesized by changing different parameters to optimize the encapsulation and 
release profiles. Local delivery of imatinib mesylate to the post-surgical tumoral 
cavity using biodegradable microspheres may be a promising biologically selective 
approach to prevent the recurrence of craniopharyngiomas via inhibition of 
neovascularization. Prof.Dr.Tuker Kilic’s group at Marmara University tested 
whether controlled release of imatinib mesylate can suppress the cranipharyngioma-
induced neovascularization in an in vivo rat cornea angiogenesis model. 
In this study, we present 3 groups of PLGA microspheres with the ratios 50:50, 
75:25 and 85:15 with different LA: GA contents that successfully inhibit tumor 
induced neovascularization in an in vivo angiogenesis model. The physicochemical 
features of the PLGA- imatinib mesylate microspheres were shown in Table 4.3. 
Table 4. 3: The physicochemical characterization of imatinib mesylate loaded PLGA 
         microspheres. 
Polymer 
Drug 
Loading 
(gr) 
Lactic acid 
(LA) and 
Glycolic 
Acid (GA) 
Ratio 
Size 
(µm) 
Encapsulation 
Efficiency  
(%) 
PLGA 0,05 50:50 58,82 36 
PLGA 0,05 75:25 76,64 21,39 
PLGA 0,05 85:15 61,23 18,75 
 
After sterilization under UV for 30 min, each of 3 imatinib mesylate containing 
microspheres and imatinib mesylate-free control microsphere were implanted 
together with tumor sample and microsphere-free recurrent craniopharyngioma 
sample was also implanted to the other eye of the rat as a negative control. These 
microspheres were formulated to release their contents within a time frame of 4-5 
weeks which is the maximum technically possible time window for corneal assay. 
For data collection, each corneas were photographed on days 5, 10, 15, 20, 25 and 30 
after implantation using a digital video camera attached to a biomicroscope, and 
vessel counting was performed by a researcher who was blinded to the study. Those 
rats with signs of ocular infection in the eye were excluded and replaced with healthy 
animals (with the same procedure and tissue sample).  
30 days follow-up in cornea angiogenesis assay showed that PLGA microspheres 
with 50:50, 75:25 and 85:15 LA: GA ratios, irrespective of their imatinib mesylate 
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contents, inhibited tumor induced neovascularization on an avascular cornea shown 
in Figure 4.22. These 30-35 μg imatinib mesylate loaded 3 microspheres release at 
first day efficiently inhibited the tumor neovascularization.  
 
Figure 4. 22: Cornea angiogenesis assay results of PLGA with LA:GA ratios 50:50, 
75:25 and 85:15 microspheres. 
The critical feature of these 3 microsphere groups is their initial burst release rates. 
Our optimization trials showed that high initial release burst is necessary for proper 
inhibition of tumor-induced neovascularization.  
In conclusion, there is urgent need for novel therapy modalities for 
craniopharyngiomas. Controlled drug delivery is an alternative to radical surgery and 
post-operative radiotherapy. Our results demonstrate that,during surgery, 
implantation of imatinib mesylate containing biodegradable PLGA microspheres into 
the surgical cavity may be a good approach to suppress the recurrence of the tumor. 
4.2 Synthesis, Characterization and Hydrolytic Degradation of Graft 
Copolymers of Polystyrene and Aliphatic Polyesters 
In this study, a new class of biodegradable graft copolymers of PS with aliphatic 
polyester  side chains were synthesized through combination of Nitroxide Mediated 
Free Radical Polymerization (NMRP) and ROP with copper (I)-catalyzed “Click” 
chemistry.  First, the click component, azido-functional PS (PS-N3) was prepared by 
copolymerization of styrene and chloromethyl styrene by NMRP followed by the 
conversion of chlorine groups of the resulting copolymer to azido groups by using 
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NaN3 in N, N-dimethylformamide. Propargyl functional aliphatic polyesters were 
prepared independently by ROP of lactic acid and glycolic acid using tin octoate in 
the presence of propargyl alcohol at 130 ˚C. Finally, PS-N3 was coupled with the 
resulting polymers by click chemistry to yield graft copolymers (PS-g-PLLA and PS-
g-PLLGA, respectively). The intermediates and final graft copolymers were 
characterized by 1H-NMR and FT-IR spectral, and GPC chromatographic analyses. 
The hydrolytic degradation behavior of the obtained graft copolymers in PBS were 
investigated by the weight loss and molecular weight measurements.  
4.2.1 Synthesis and characterization of PS-g-PLLA and PS-g-PLLGA graft 
copolymers 
For the synthesis of parent azide functionalized polymer, we first prepared 
poly(styrene-co-chloromethylstyrene), P(S-co-CMS), via NMRP of styrene (S) and 
chloromethylstyrene (CMS) at 125 °C according to the procedure. NMRP was 
delibaretly selected as the controlled radical polymerization method for its suitability 
for the polymerization of S based monomers and tolerance to halide functional 
groups. The composition of copolymer was determined using 1H NMR spectroscopy. 
The mole fractions of CMS and S were calculated from the ratio of the peak areas 
around 4.5 ppm, corresponding to two methylene protons of in the side chain of 
CMS to the total area between 6.3 and 7.4 ppm, which was attributed to the total 
aromatic protons (Figure 4.23). P(S-co-CMS) with Mn(GPC) 7.690 and 16 mol % 
chloromethyl groups was then quantitatively converted into polystyrene-azide (PS-
N3) in the presence of NaN3/DMF at room temperature. From the 
1H NMR spectrum 
of PS-N3 shown in Figure 4.23, it was observed that while the signal at 4.5 ppm 
corresponding to CH2-Cl protons of the precursor P(S-co-CMS) completely 
disappeared, and a new signal appeared at 4.25 ppm due to CH2 linked to azide 
groups. The structure of PS-N3 was further supported by the observation from FT-IR 
spectrum of the azide stretching band at 2094 cm-1 (vide infra). 
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Figure 4. 23 : 1H NMR spectra of P(S-co-CMS), PS-N3, PS-g-PLLA and PS-g-
PLLGA. 
The second step in the synthesis of PS with biodegradable side chains was to obtain 
alkyne functionalized polymers (PLLA or PLLGA). To obtain the desired 
functionalities, combined with proper molecular weights and polydispersities, 
polymers were synthesized by ROP of L-lactide and glycolide, respectively by using 
propargyl alcohol as a functional initiator, in the presence of stannous octoate. In 
both cases the GPC traces are unimodal and narrow, indicating that no important side 
reactions occurred. Moreover, as these polymers were intended to be used in the 
subsequent click reactions, efforts were directed toward obtaining low molecular 
weights, combined with convenient yields. Some characteristics are presented in 
Table 4.4. Finally, the obtained PLLA and PLLGA containing acetylene groups were 
clicked to PS-N3 to yield PS-g-PLLA and PS-g-PLLGA, respectively by copper 
catalyzed cyclo addition reaction (see Figure 3.1). After the click reaction, new peaks 
appeared at around 1.58, 3.48 and 5.13 ppm for PS-g-PLLA copolymer, and 1.58, 
3.48, 4.81 and 5.13 ppm for PS-g-PLLGA copolymer which correspond to PLLA 
and PLLGA segments of the graft copolymers, respectively.  
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Table 4. 4: The yields of the reactions and molecular weight characteristics of the 
products at different modification stages. 
Polymer Yield (%) Mn, NMR
a Mn, GPC
b Mw /Mn
b 
P(S-co-CMS) 85c - 7690 1,21 
PS-N3 100
d - 8070 1,20 
PLLGA 60c 2660 2870 1,23 
PS-g-PLLGA 75e 10730 8370 1,68 
PLLA 65c 1570 3520 1,30 
PS-g-PLLA 69e 9640 15120 1,51 
a Determined by 1H NMR analysis. 
b Determined by gel permation chromatography (GPC) using polystyrene standards. 
c Conversion of monomers as determined gravimetrically. 
d Conversion of the chlorine groups to azide groups. 
e Yield of the Click reaction determined by 1H NMR analysis. 
 
The graft copolymer formation was also followed by FT-IR spectroscopy. The FT-IR 
spectrum associated with graft copolymers showed the presence of both components 
(PS and PLLA or PLLGA) in the structure (Figures 4.24 and 4.25). Peaks resonating 
at around 1800 and 1200 cm-1 were due to carbonyl groups and C-O bonds of the 
PLLA and  PLLGA side chains whereas transitions from 1595, 1490, and 700 cm−1 
and overtones between 1945 and 1805 cm−1 were specific to the PS main chain. As 
anticipated, the azide stretching band of the precursor polymers at 2100 cm-1 
decreased significantly. However, it did not disappear completely probably due to the 
steric hindrance [133].  
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Figure 4. 24: FT-IR spectra of PS-N3 and PS-g-PLLA. 
 
 
Figure 4. 25 : FT-IR spectra of PS-N3 and PS-g-PLLGA. 
 
Sucessful grafting was also confirmed by GPC measurements. In Figures 4.26 and 
4.27, the normalized GPC curves of the individual precursor polymers as well as of 
the resulting graft copolymers were shown. In the elution curves of graft copolymers, 
although slight shoulders of the chromatographic peak corresponding to precursor 
polymers are noted, clear shifts toward lower retention times were observed. These 
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observations confirm that the described click approach is useful for the desired graft 
copolymer formation. 
 
Figure 4. 26 : GPC traces of P(S-co-CMS), PS-N3, PLLA and PS-g-PLLA. 
 
Figure 4. 27 : GPC traces of P(S-co-CMS), PS-N3, PLLGA and PS-g-PLLGA. 
The yields of polymerization, modification and click reactions and the molecular 
weight characteristics of the resulting polymers are collected in Table 4.4. As can be 
seen, the measured molecular weights generally fit with those determined by 1H 
NMR analyses. Some discrepeancies observed may be due to the different 
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hydrodynamic volumes of the graft copolymers and strong interactions of the polar 
segments with the stationary phase of the GPC column. It is also noted that no side 
reactions such as coupling or chain scission occured during the azidation process and 
the molecular weight of the precursor polymer was preserved. 
4.2.2 Hydrolytic degradation of graft copolymers 
Preliminary studies were conducted to study the hydrolytic degradation behavior of 
the graft copolymers. The hydrolytic degradation behavior of the graft copolymers 
were carried out in phosphate buffer saline at pH 7.4 and 37˚C as described in the 
Experimental Section. Typical GPC curves of PS-g-PLLGA before and during 
hydrolytic degradation are shown in Figure 4.28.  
 
 
Figure 4. 28 : GPC traces of PS-g-PLLGA during hydrolitic degradation stage. 
As can be seen, during hydrolysis the molecular weight peak of the graft copolymer 
is gradually shifted to a low-molecular weight region, thereby showing the hydrolytic 
degradation capability of  the new graft copolymers synthesized. The degradation 
behavior of the graft copolymers was also followed by mass losses of the polymers. 
Figures 4.29 and 4.30 compare the molecular weight and mass losses of PS-g-PLLA 
and PS-g-PLLGA, respectively during the hydrolytic degradation.  
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Figure 4. 29 : Mass losses for PS-g-PLLA and PS-g-PLLGA. 
 
Figure 4. 30 : Molecular weight losses for PS-g-PLLA and PS-g-PLLGA. 
In both cases, similar two-stage degradation patterns were observed. The initial slow 
degradation is leveled off at four weeks. The relatively faster rate observed after this 
point may be due to the autocatalytic degradation favored by the acid released.   
Relatively faster rate of the degradation observed with the PS-g-PLLGA polymer is 
due to the presence of hydrophilic glycolide groups present in the structure. The 
degradations occured through ester groups (lactic acid and glycolic acid repeating 
units). This was confirmed by the 1H-NMR spectroscopy. Although the 1H-NMR 
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spectra of the chloroform extracted degradation products were complex for a definite 
estimation, they clearly indicated that the remaining product was mainly polystyrene.  
4.2.3 In vitro release studies of PS-g-PLLA and PS-g-PLLGA 
In this study, we describe the fabrication, characterization and in vitro release studies 
of microspheres of PS-g-PLLGA, PS-g-PLLA and PLLGA. PS-g-PLLA, PS-g-
PLLGA and PLLGA were synthesized as described in section 3.3.2. 
The in vitro release studies were performed at 37˚C in PBS at pH 7.4. Encapsulation 
efficiencies, drug loadings and initial burst releases of the microspheres are listed in 
Table 4.5. The optimized method of previous study involving the effect of conditions 
on particle size, surface morphology and controlled release behavior was used in this 
work. 
Microspheres of these biocompatible copolymers fabricated through modified double 
emulsion/solvent evaporation method as described in section 3.3.1. Imatinib 
mesylate was used as a hydrophilic drug for encapsulation. Entrapment efficiencies 
and in vitro release studies of the imatinib mesylate microspheres were monitored by 
a high performance liquid chromatography (HPLC) assay. Stages of degradation and 
surface morphology of the loaded microspheres were determined by scanning 
electron microscopy (SEM). 
Table 4.5:Encapsulation efficiencies (EE) and burst releases of drug loaded 
microspheres. 
Polymer 
EE 
(%) 
Burst release 
      (%) 
PS-g-PLLA 77 ± 0,5 30,66 ± 0,28 
PS-g-PLLGA 89 ± 1,44 8,34 ± 0,22 
PLLGA 58 ± 3,32 4,65 ± 3,59 
 
Molecular weights of the aliphatic polyester chains of PS graft copolymers were 
intended to keep closer to the molecular weight of the PLLGA copolymer for a 
proper comparison on controlled release profiles, size distribution and surface 
characteristics of the microspheres. 
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The degradation of polymeric microspheres were studied in PBS at pH:7.4 and 37 
ºC. As shown in Figure 4.31, microspheres were in good spherical shape. The PS 
backbone of the graft copolymer provides a smooth surface without signs of major 
degradation during 35 days of incubation. PS-g-PLLGA graft copolymer showed 
nearly similar degradation behaviour with the PS-g-PLLA (Figure 4.32).  The effect 
of glycolic acid units on the degradation was noted after 35 days. SEM images of 
microspheres of PLLGA copolymer indicate that the surfaces of the microspheres 
were smooth for the first 4 days (Figure 4.33). In a prolonged incubation, the 
microspheres started to lose smoothness and an increase in porosity of surface was 
observed by the initiation of the degradation.  By day 25, the microspheres degraded 
to an extent that all spherical morphology was lost.  On the other hand, microspheres 
of PS-g-PLLA remain smooth on 35th day as the first day. 
 
Figure 4. 31: SEM micrographs of PS-g-PLLA microspheres following in vitro 
                         degradation over a period of 35 days: a) 0 day; (b)4 days; (c) 19 days;  
(d)35 days. 
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Figure 4. 32: SEM micrographs of PS-g-PLLGA microspheres following in vitro 
degradation over a period of 35 days: a) 0 day; (b)4 days; (c) 19 days;      
(d)35 days. 
SEM photo of PLLGA microspheres points out the increasing porosity and loosing 
smoothness by the initiation of degradation due to the influence of glycolic acid units 
presence in the structure.  On the other hand, microspheres of PS-g-PLLA remains as 
smooth as the first day. It is clear that PS backbone of graft copolymers contributes 
to retard the effect of glycolic units on degradation. This statement is independent of 
the molecular weight effect since Mw of aliphatic side chains of the graft copolymers 
close to the PLLGA copolymer.  According to the morphological studies, it can be 
concluded that the composition of the polymers plays a dominant role in the 
degradation behaviour. The in vitro release studies of imatinib mesylate from PS-g-
PLLGA, PS-g-PLLA and PLLGA microspheres were performed at 37˚C in PBS at 
pH:7,4 for 25-35 days. The influence of the structure of graft copolymers on daily 
and cumulative release of imatinib mesylate-loaded microspheres is shown in Figure 
4.34 and 4.35, respectively. In the case of PS-g-PLLA, 153 μg/mL of the 
encapsulated IMM was released on the first day of incubation (Figure 4.34). For PS-
g-PLLGA and PLLGA copolymer, the burst releases were 91 μg/mL and 15 μg/mL, 
respectively. Burst releases of the microspheres are quite high for PS-g-PLLA 
Create PDF files without this message by purchasing novaPDF printer (http://www.novapdf.com)
77 
suggesting the presence of the drug either stored close to the surface or remained on 
the surface during the preparation. 
 
Figure 4. 33: SEM micrographs of PLLGA microspheres following in vitro 
                      degradation over a period of 25 days: a) 0 day; (b)4 days; (c) 10 days;  
(d)25 days. 
Although such behaviour is not normally desired, in a previous study we showed that 
the burst release of imatinib mesylate is an important factor on inhibition tumor-
induced neovascularization .  
 
Figure 4. 34: Daily imatinib mesylate release profiles of PLLGA, PS-g-PLLA and 
PS-g-PLLGA  microspheres. 
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Imatinib mesylate release increased up to 25 and 35 days for PLLGA and PS-g-
PLLGA copolymers, respectively. Although there was no appearant degradation of 
PS-g-PLLA microspheres on the 35th day of incubation (vide ante, see Fig. 4.32), 
drug release was still carried on (Figure 4.35). It should also be pointed out that it 
showed an initial burst release followed by steady-state release until 35 days. 
 
 
Figure 4. 35: Cumulative imatinib mesylate release profiles of PLLGA, PS-g-PLLA 
and PS-g-PLLGA microspheres. 
 
Comparison of the graft copolymers of PS with PLLGA copolymer revealed that PS 
segments introduces durability and control the release of the drug that SEM images 
of the microspheres which is in agreement with the above statement. During the first 
20 days, release profiles were similar for PS-g-PLLA and PS-g-PLLGA when burst 
effects were neglected. But, after 20 days, significant increase in release rates were 
observed for PS-g-PLLGA microspheres which can be explained in terms of higher 
degradation rate caused by increasing hydrophilicity and porosity of the surface.  
In spite of low degradation profiles, PS-g-PLLA and PS-g-PLLGA released 
approximately 45% and 70% of total encapsulated drug during 35 days, respectively. 
On the other hand, PLLGA released the entire drug at the end of 25th day because of 
the glycolic acid units in the structure (Figure 4.35).  Prolonged release in the former 
case indicates the influence of the diffusion rather than degradation provided by the 
polymer matrix.  
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4.3 Synthesis, Characterization and Pyrolysis of ABC Type Miktoarm Star PS-
PLA-PEG Copolymer 
Introduction of the click chemistry concept to the synthetic polymer chemistry 
enabled construction of various macromolecular blocks [137].  Click reactions are 
modular, high yielded rapid reactions with negligible by-product formation. The very 
well known click reactions include CuAAC [138-140] and Diels-Alder (DA) [137-
142] reactions which are realized by the coupling of a conjugated diene and a 
dienophille. In the present study, we prepared a novel miktoarm star polymers 
possessing structurally different arms, namely PS, PEG and an aliphatic polyester, 
PLA. Such polymers are of interest particularly in biological application since 
respective hydrophobic, hydrophilic and biocompatible segments are linked together 
through a central core. It seemed appropriate to investigate their thermal degradation 
behavior since independent segment may influence their overall degradation 
behavior.   
4.3.1. Synthesis and characterization of ABC type miktoarm star PS-PLA-PEG 
copolymer 
The synthetic strategy is based on the design of a core molecule possessing 
appropriate functionalities for the initiation of the ring opening polymerization and 
two successive click reactions, namely thiol-ene and azide-alkyne cycloaddition 
reactions. The core was synthesized in a simple one-step reaction strategy. Thus, 
allyl glycidyl ether was reacted with sodium azide in the presence of ammonium 
choride using ethanol/water (Figure 4.36) with nearly quantitative yield (96%). The 
structure of the core was confirmed by 1H-NMR and FT-IR analyses as shown in the 
experimental section.  
 
Figure 4. 36 : Synthesis of the core, 1-(allyloxy)-3-azidopropan-2-ol 
Considering the possible involvement of the allylic group in the further reactions, in 
the first stage thiol-ene reaction was deliberately selected for the incorporation of the 
first arm to the core. Thus, ω-thiol functional polystyrene (PS-SH) was synthesized 
in a two-step protocol as described previously [146]. For this purpose, ω-bromo 
functional polystyrene obtained via Atom Transfer Radical Polymerization (ATRP) 
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is reacted with potassium xanthate where the ω-terminus is converted into xanthate 
functionality to yield PS-Xanth. Afterwards, the xanthate group is replaced with thiol 
functionality simply treating PS-Xanth with 1,2-ethandithiol in the presence of 
metallic zinc to give PS-SH. The overall process is given in Figure 4.37. 
 
Figure 4. 37 : Synthesis of ω-thiol functional polystyrene, PS-SH. 
In the later stage, PS-SH was clicked to the core by thiol-ene chemistry. Thus, PS-SH 
was reacted with the core in the presence of a photolabile compound, BAPO upon 
visible light irradiation. According to the 1H-NMR data, the yield of the reaction is 
found to be realized with 95%. The thiol-ene process is shown in Figure 4.38. 
 
Figure 4. 38 : Thiol-ene click of PS-SH with the core, PS-core. 
Next, L-lactide was polymerized from the hydroxyl functionality to afford the second 
arm of the star copolymer in the presence of Sn(Oct)2 as catalyst. Parallel to this, 
acetylene functional PEG was synthesized via a simple esterification reaction 
between ω-hydroxy functional PEG (Me-PEG) with 4-pentynoic acid for the 
polymeric CuAAC click component (PEG-acetylene). Finally, PEG-acetylene was 
clicked to the azide functionality simply by CuAAC using CuBr as catalyst (Yield: 
94%, according to the 1H-NMR data). The overall process is demonstrated in Figure 
4.39. The 1H-NMR of the miktoarm star copolymer, PS-PLA-PEG, is shown in 
Figure 4.40. All characteristic peaks of each segment can be clearly identified 
confirming realization of the final structure. 
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Figure 4. 39 : Construction of the second (PS-PLA-N3) and third arm (PSA-PLA-
PEG) of the star copolymer. 
 
Figure 4. 40 : 1H NMR of the miktoarm star copolymer. 
The GPC chromatograms of the polymers in each step are depicted in Figure 4.41. 
All polymers display unimodal GPC traces confirming the absence of side reactions 
such as chain scission or any unwanted coupling reactions like disulfide formation.  
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Figure 4. 41 : GPC traces of polymers obtained in each step. 
The molecular weight characteristics of polymers obtained in each step are collected 
in Table 4.6.  
Table 4. 6 : Molecular weight characteristics of polymers at various stages. 
Polymer 
Mn,NMR
a 
(g·mol-1) 
Mn,GPC
b 
(g·mol-1) 
Mw/Mn
b 
PS-Br 2030 1910 1.19 
PS-Xant -c 2200 1.20 
PS-SH 1980 1950 1.18 
PS-core 2270 2250 1.18 
PS-PLA-N3 3480 2860 1.32 
PEG 1950 2100 1.15 
PS-PLA-PEG 5940 3010 1.21 
a Determined by 1H NMR analysis. 
b Determined by gel permeation chromatography (GPC) using polystyrene standards. 
c Could not be determined due to partial insolubility.  
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4.3.2 Pyrolysis of of ABC type miktoarm star PS-PLA-PEG copolymer 
The thermal degaradation behavior of the final miktoarm star copolymer PS-PLA-
PEG was investigated by J. Hacaloglu et.al. Direct pyrolysis mass spectrometry was 
used to study the thermal degradation behavior of PS-PLA-PEG. As, pyrolysis mass 
spectra of polymers, especially the ones involving different chains, are usually very 
complex, for the elucidation of thermal degradation behavior of PS-PLA-PEG, DP-
MS analysis of intermediate structures PS-SH, PS-core, PS-PLA-N3 were also 
performed.                      
Thermal degradation of PS-PLA-PEG started just above 100 C.  The total ion 
current curve shows five overlapping peaks with maxima at 180, 250, 330, 370, and 
450C (Figure 4.42).  Peaks diagnostic to PEG side chains appeared in the mass 
spectra at early stages of pyrolysis.  Peaks due to decomposition of PLA chains were 
observed in the temperature range of 220 – 380 C and those due to PS degradation 
were detected in the final stages of pyrolysis at around 441 C. Single ion evolution 
profiles of diagnostic products of PEG, PLA and PS units are shown in Figure 4.39.  
In general a slight decrease in thermal stability compared to PS-PLA-N3 was 
detected. Even the evolution of PS based products shifted slightly to low 
temperatures. It is known that during the thermal degradation of PEG, the fragments 
generated by cleavage of C-O and C-C bonds are stabilized by hydrogen transfer 
reactions, yielding low mass chains with methyl, ethyl, hydroxyl, aldehyde and 
unsaturated end groups [147-153]. It has been determined that at the onset of 
pyrolysis, products with ethyl and hydroxyl end groups are dominant [154]. The 
evolution profiles of diagnostic products of PEG showed two peaks, the first being 
more intense, with maxima at around 169 and 240C. All products except the ones 
that can also be generated during the decomposition of PLA showed almost identical 
trends. The products involving unsaturated end groups were more pronounced even 
at low temperatures contrary to literature results. It may be thought that these end 
groups were mainly produced by elimination of H2O from chains with alcohol end 
groups as shown in Figure 4.43. The low temperature peaks present in the evolution 
profiles of PLA based products were attributed to contribution of PEG based 
products with the same m/z value. Nevertheless, a slight decrease in the thermal 
stability of PLA chains compared to PS-PLA-N3 was detected. The maxima of the 
two peaks present in the evolution profiles of PLA based products were shifted to 
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300 and 363C from 308 and 377C respectively. It may be thought that the 
possibility of decomposition of PLA chains by hydrolysis should increase 
significantly due to the evolution of H2O during the degradation of PEG chains.      
 
 
 
Figure 4. 42: a. TIC curve and pyrolysis mass spectra at b. 163, c. 222, d. 305, e. 365 
and f. 441C of PS-PLA-PEG. 
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Figure 4. 43: Single ion evolution profiles of selected products recorded during the 
pyrolysis of PS-PLA-PEG. 
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Figure 4. 44: Elimination of H2O during the thermal degradation of PEG. 
As a consequence, the chains bearing acid and alcohol end groups should be more 
dominant. This in turn, should enhance CO2 and CO evolutions. Generation of 
CH3C2H2CH3, COOH, CO2 and CO was detected at slightly higher temperatures 
again supporting the proposed degradation mechanism (Figure 4.44).  A slight 
increase in the yields of CO2 and CO was also noted. One point that should also be 
noticed was the significant increase in the intensities of the high temperature 
shoulder present in the evolution profiles of products with m/z=128 and 217 Da 
tentatively assigned to C10H8 and C17H13 fragments involving unsaturation and/or 
crosslinked structures. Again a high temperature peak in the evolution profile of 207 
Da fragment at around 452 C was detected.  
These findings were in accordance to above proposals, and confirmed the increase in 
the extent of chains with acid end groups and anhydride units as a result of 
hydrolysis reactions due to the elimination of H2O during the decomposition of PEG 
chains.  Consequently, the increase in the extent of unsaturated and crosslinked units 
was supported. 
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5. CONCLUSIONS 
New biopolymers are needed in biomedical applications because of the complexity 
of in vivo environments. Synthetic biopolymers have become an attractive 
alternatives caused by the difficulties on chemical modifications of biologically 
derived biopolymers and instead of having good biocompability but triggering an 
immune response in human body of biologically derived polymers.  In this thesis, we 
describe novel synthesis of new biodegradable polymers to ensure the demand. 
These biodegradable polymers are expected to cover deficiencies of biopolymers and 
take place in practical applications. 
In the first part, we aimed to prepare microspheres made of commercial 
biodegradable polymers at different conditions to optimize a method for further 
investigations. Polymers with a different molecular weights and compositions are 
used for comparison. Surface characteristics and controlled release profiles of 
synthesized microspheres are examined. As a result of this work optimized 
microspheres were chosen for in vivo experiments. The results indicate that a model 
drug loaded microspheres are a promising way for treatment. 
In the second part, we have demonstrated that biodegradable graft copolymers of 
polystyrene and aliphatic polyesters of the following structure (Figure 5.1)  could 
easily be synthesized by combination of controlled polymerization methods (NMRP 
and ROP) and click chemistry.  
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Figure 5. 1 : Chemical structure of PS-g-PLLA and PS-g-PLLGA graft copolymers. 
The structural characterization of the graft copolymers were made by spectral and 
molecular weight analyses. The resulting graft copolymers showed slow hydrolytic 
degradation profile. The graft copolymers with PLLGA side chains degrade faster 
relatively due to the hydrophilic nature of the glycolic acid repeating units.  Due to 
their slow degradation, these copolymers are ideally suitable for long-term drug 
delivery usage. In vitro release studies and surface morphologies of the 
miscropeheres formed from the graft copolymers confirm the statement. 
In the third part, an ABC type miktoarm star copolymer possessing PS, PLA and 
PEG arms was synthesized by combining ATRP and ROP with two click 
chemistries, namely thiol–ene and copper catalyzed azide–alkyne cycloaddition 
(CuAAC) (Figure 5.2).   
 
Figure 5. 2 :Chemical structure of ABC type miktoarm PS-PLA-PEG star 
copolymer. 
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All intermediates, related polymers at different stages and final PS-PLA-PEG 
miktoarm star copolymer were characterized by 1H NMR, FT-IR, and GPC analyses. 
Thermal degradation studies are performed in order to obtain information for the 
future applications of the polymer in the biomedical field. DP-MS analyses indicated 
that the decomposition of PS and PEG chains occurred almost independently.  On the 
other hand, as a consequence of hydrolysis of PLA chains by H2O eliminated during 
the thermal degradation of PEG chains, thermal degradation of PLA was affected. As 
a result, increases in the yields of CO2, CO and units involving unsaturation and/or 
crosslinked structure were detected. 
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